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Abstract
Purpose: To assess the clinical significance of different regulatory	T cells
(Treg) attracting chemokine intratumoral expressions in breast and ovarian
cancer patients with available long-term follow-up (15 years). We investigated
the prespecified hypothesis that the expression of Treg specific chemokines in
cancer tissue predicts the overall	survival (OS).
Patients and Methods: We screened all so far known chemokines of the CC-
family for their capacity to selectively attract Treg in vitro. Three chemokines
(CCL1, CCL22, and CCL27) with selective action on Treg migration were
stained using extensively characterized antibodies. The numbers of positive
cells in tissue microarray cores from ovarian cancer and invasive breast cancer
were computer-aided determined.
Results: Within all analyzed chemokines, only CCL1, CCL22 and CCL27
selectively attracted Treg in vitro. All three chemokines were strongly ex-
pressed in most ovarian and breast cancer tissues. Moreover, there was a
significant relationship between Treg infiltration in tumors and CCL1- and
CCL27-expressing cell total numbers, whereas no association was seen for
CCL22. High numbers of CCL1- or CCL27-positive cells identified patients
with shorter OS.
Conclusion: Our findings indicate that quantification of intratumoral Treg
attracting chemokines in ovarian and breast cancer is valuable for assessing
disease prognosis. Unlike conventional clinicopathologic factors, high expres-
sion of certain chemokines can identify patients at risk of death over 15 years.
CCL1 and CCL27 represent novel markers for identifying effect of immune
response and tumor escape as well as patients who may benefit from immuno-
therapy. Such chemokines may gain to be considered together and could rep-
resent important therapeutic targets.
Key words: regulatory T cells, chemokine, CCL1, CCL27, ovarian cancer,
breast cancer, clinical outcome, biomarker, therapeutic target, cancer immuno-
therapy.
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Zusammenfassung
Zielsetzung: Untersuchung der klinischen Signifikanz von intratumoral ex-
primierten Chemokinen bei Mamma- und Ovarialkarzinompatientinnen mit
Langzeit-Follow-up (15 Jahre) und deren Einfluss auf die Infiltration regula-
torischer T-Zellen (Treg). Untersucht wurde die Hypothese, dass die Expres-
sion Treg spezifischer Chemokine in Karzinomgeweben das Gesamtüberleben
beeinflusst.
Patientenkollektiv und Methode: Überprüft wurden alle bisher bekannten
Chemokine der CC-Familie auf die selektive Kapazität Treg Migration in
vitro auszulösen. Drei Chemokine (CCL1, CCL22 und CCL27), die die Treg
spezifisch anlocken, wurden mit getesteten Antikörpern gefärbt. Die Anzahl
positiver Zellen in Microarray-Gewebsschnitten von Ovarial- und invasiven
Mammakarzinomen wurden mit Hilfe eines Computerprogramms bestimmt.
Ergebnisse: Von allen untersuchten Chemokinen, lockten nur CCL1, CCL22
und CCL27 Treg in vitro an. Die meisten Ovarial- und Mammakarzinom-
gewebe zeigten eine starke Expression dieser drei Chemokine. Weiterhin
bestand ein signifikanter Zusammenhang zwischen Treg-Infiltration ins Tu-
morgewebe und der Gesamtanzahl CCL1- sowohl als auch CCL27- exprim-
ierender Zellen, während kein Zusammenhang mit CCL22 gefunden wurde.
Eine hohe Anzahl an CCL1 oder CCL27 positiver Zellen ging einher mit
verkürztem Gesamt-überleben.
Schlussfolgerung: Unsere Ergebnisse weisen darauf hin, dass Treg anlock-
ende Chemokine in Ovarial- und Mammakarzinomen von prognostischer Be-
deutung sind. Im Gegensatz zu konventionellen klinikopathologischen Fak-
toren, identifiziert eine hohe Expression bestimmter Chemokine Patientinnen
mit erhöhtem Risiko innerhalb der nächsten 15 Jahre an dem Karzinom zu ver-
sterben. CCL1 und CCL27 stellen neue Marker zur Untersuchung der Immu-
nantwort und der Reaktion des Tumors diese zu umgehen dar. Des Weiteren
dienen diese beiden Chemokine zur Identifizierung der Patientinnen, die von
einer Immuntherapie profitieren würden. Eine Kombination von CCL1 und
CCL27 könnte in Zukunft ein wichtiges therapeutisches Target darstellen.
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Introduction 1
— It	is	by	no	means	inconceivable	that	small	accumulations	of	tumour
cells	may	develop	and, because	of	their	possession	of	new	antigenic	po-
tentialities, provoke	an	effective	immunological	reaction	with	regression
of	the	tumour	and	no	clinical	hint	of	its	existence.
Macfarlane	Burnet, immunologist, 1957
1.1 The immunology of tumors
1.1.1 A short story of the immune regulation
The balance between effector response and mechanisms of immune regulation isone of the fundamental features of the immune system: the ability to correctly
respond to any external aggression or infectious microorganism avoiding destruction
of self-tissues determines its role [1]. This original paradigm was claimed more than
fifty years ago by Medawar et al. and derived nowadays to include the pharmacologi-
cal induced state of tolerance against any deliberately introduced antigen, as it is the
case for a transplanted organ. From an evolutionary point of view, the critical im-
portance of the immune tolerance is illustrated by the multitude of non-redundant
mechanisms [2].
It is currently well accepted that immunological tolerance is mediated by two
categories of mechanism: central and peripheral. After a first cellular selection in
the thymus, the functionality and efficiency of the immune system is highly de-
pendent on complex series of cellular and cytokine mediated interactions between
effector and regulatory cells. In the periphery, effector but also regulatory cells have
to be recruited both at the right place and at the right time, via complex chemokine
networks coordinating cell traffics.
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Figure 1.1 – Tumor anatomy showing the immune contexture of cancer with features of the
immune contexture and the distribution of different immune cells according to Fridman et al.. DC,
dendritic cell; MDSC, myeloid-derived suppressor cell; Treg, regulatory T cell; NK cell, natural
killer cell; FDC, follicular dendritic cell; TLS, tertiary lymphoid structure.
These chemokines consist of small chemotactic cytokines characterized by criti-
cally positioned cysteine residues that are recruiting distinct cell types according to
their corresponding receptors [3, 4]. Corresponding chemokine receptors are spe-
cifically regulated in regard of cell type, stage of activation and differentiation [5].
Given the central role of chemokines in the regulation of cell migrations, it was
obvious that they also play a pivotal role in the regulation of the peripheral immune
response. They allow the regulation of the adaptive immune response by recruiting
effector cells, but also immunoregulatory cells. So far, over 50 chemokines and 22
chemokine receptors have been identified and their central function in the coordi-
nation of the immune system is now firmly established [6].
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1.1.2 Role of the immune system in cancer
Many of the defenses against the appearance of cancerous growths are inherent in
cells. The most obvious one lying in the different controls imposed by the apop-
totic machinery. During the past decades, however, several authors linked human
cancer progression with immune cell infiltration [7, 8, 9]. This followed the first
observations realized in mice by Hanahan and Weinberg, which had led them to
add “avoid immune destruction” as a hallmark of cancer [10]. In fact, tumor en-
vironments are an intricate network of epithelial cells, vascular and lymphatic ves-
sels, cytokines, chemokines and infiltrating immune cells. All immune cells can be
found in a tumor, including dendritic	cells (DC), macrophages, natural killer cells,
naive and memory lymphocytes, B cells and various subsets of T cells – Figure 1.1,
p. 2 [11]. Moreover, these different cell types seem to play a role which can vary
according to the tumor nature and his localization: sometimes favorable, or in some
other cases, paradoxically accelerating the tumor growth and reducing the OS of
patients [12, 13].
The demonstration of the infiltrated cell influence on the clinical outcome of
cancer conducted to the creation of the field of tumor immunology and already led
to novel opportunities of prognostic marker identification and therapeutic options.
Histopathological studies of human tumors have shown that variable numbers of
infiltrating immune cells are found in different tumors of the same type, and are
found at different localizations within and around a tumor; this distribution also
varies between tumor types [14]. This is underlying the possibility of different roles
for these immune cell populations, in respect to their localizations in tumors, but
also the complexity of the role played by the immune system in cancer.
The observation of variable densities and localizations of these immune cells
between tumors of the same cancer type in different individuals tends to prove the
orchestrated fine migration of these cells. Considering the role of chemokines in cell
migration, it was not surprising to find overexpressed chemokine synthesis in several
tumor types, possibly responsible for the accumulation of immune cells [15, 16].
These issues are far from being completely answered, but analyses of the cytokine
and chemokine milieu associated with a tumor immune contexture are accumulating.
Moreover, this suggests that the immune system could indeed represent effective
defenses that prevent the appearance of tumors.
1.1.3 Clinical impact of the immune contexture
One century ago Paul Ehrlich proposed that the immune system is programmed to
avoid the generation of autoreactive immune responses and termed this aversion to
autoreactivity “horror autotoxicus”. Ehrlich’s observations that goats could make anti-
bodies against the blood components of other goats, but not against their own blood,
represented the first evidence of immunological self-tolerance. However, nowadays,
it clearly appears that an absence of immune response is as much deleterious for the
organism.
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Correlations between tumor levels of immune cell infiltration and clinical out-
come have been investigated in many cancers and results are still a matter of debate
since they present some contradictions. A strong lymphocytic infiltration has been
reported to be associated with good clinical outcome in many different tumor types,
including melanoma, head and neck, breast, bladder, urothelial, ovarian, colorectal,
renal, prostatic and lung cancer [11]. Precisely, high densities of cluster	of	differen-
tiation (CD)3+ T cells, CD8+ cytotoxic T cells and CD45RO+ memory T cells were
commonly associated with better prognosis [17, 18].
In contrast, analysis of the CD4+ T cell population infiltration often shows an
opposite effect on OS. Most conflicting are the different data for T helper	cells (Th)2,
Th17 and Treg, linked with difficult interpretations [11]. This is presumably due to
the creation of an immunosuppressive micro-environment, inhibiting any chance
of a correct immune response against tumor cells and thus leading to accelerated
tumor growth and reduced OS. This immune contexture in tumor could serve
to predict therapeutic responses, as shown in the colorectal cancer and the breast
cancer. Considering the number of infiltrated cytotoxic CD8+ cells and memory
CD45RO+ cells, Denkert et al. and Tosolini et al. could finely predict the risk of
relapse when no other actual markers could do it [18, 19]. This of course, could be
of paramount importance in patient clinical management, but also allows to target
the accumulation of unfavorable immune cells; thus opening the way to interesting
new therapeutic opportunities of treatment.
1.1.4 Emergence of the immunotherapy
During the last two decades, cancer treatments evolved from relatively nonspe-
cific cytotoxic agents to selective, mechanism-based therapeutics. Although cancer
chemotherapies initially were compounds that killed rapidly but unspecifically divid-
ing cells, improved understanding of cancer pathogenesis has given rise to new treat-
ment options, including targeted agents and cancer immunotherapy. Among these
modern targeted approaches, immunotherapy aims to stimulate a host immune re-
sponse that effectuates long-lived tumour destruction to improves clinical outcome,
reduces toxicities and frequently acquired resistances. Significant advances in target-
ing the immune response were made and have led to cell-based vaccine composed of
autologous antigen	presenting	cells (APC) that have been exposed to a recombinant
protein consisting of granulocyte-macrophage	 colony-stimulating	 factor (GM-CSF)
fused to a protein expressed by cancer cells. Upon administration, the vaccine may
stimulate an antitumor T-cell response against tumor cells expressing this protein.
Secondly, tumour-specific T cells must differentiate into effector T cells, which
requires a combination of signals from both the T cell	receptor (TCR) and several co-
stimulatory molecules [20]. Co-stimulatory signals are delivered through multiple
transmembrane proteins of the B7 and tumour	necrosis	factor	receptor (TNFR) fam-
ilies, as well as receptors for some cytokines, such as interleukin (IL)-12. Agonistic
antibodies to these molecules can enhance co-stimulation to augment anti-tumour
immunity [21, 22]. However, T cells must avoid negative regulatory signals (known
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as immune checkpoints) that dampen their activation or that induce tolerance pro-
grammes such as anergy or exhaustion [23, 24]. Blockage of cytotoxic	T lymphocyte-
associated	antigen	4 (CTLA4) and programmed	cell	death	protein	1 (PD1), both major
negative co-stimulatory molecules that are expressed on activated T cells, are now
possible and has demonstrated encouraging anti-tumour effects in initial clinical
testing [25, 26].
A major impediment to the therapeutic efficacy of anti-tumour T cells is the
immunosuppressive tumour micro-environment [27]. Diverse mechanisms operate,
including the production of inhibitory cytokines such as IL-10 and tumor	growth	fac-
tor (TGF)-β, the expression of negative co-stimulatory ligands such as programmed
cell	death	ligand	1 (PDL1), and the presence of regulatory lymphocyte and myeloid
cell populations. The identification of agents that attenuate these suppressive net-
works might substantially increase the efficacy of immunotherapies [28].
1.2 Regulatory T cells
1.2.1 About their role in the immunoediting process
Tumors are often infiltrated by various inflammatory immune cells creating a milieu
that may function to either stimulate or inhibit cancer growth [29]. The chronic
inflammation response found in many cancers creates an environment rich in sub-
stances that promote angiogenesis and cell proliferation, very similar to wound heal-
ing processes [30]. Evidence from murine studies strongly suggest, that adaptive
immune cells are attracted and can directly eliminate tumor cells [31, 32].
Immunosurveillance, however, can fail to completely kill nascent tumors – due
to poor immunogenicity of tumor cells or immune escape mechanisms – and there-
fore favorises the immunoediting process which eventually ends in tumor escape [8].
The analysis of the location, density, functional orientation of different immune cell
populations, and their respective clinical impacts have been investigated in many
cancers [11]. The ultimate goal is to allow the identification of components of the
immune contexture that are beneficial, as well as those that are deleterious, to pa-
tients.
A strong lymphocytic infiltration, particularly CD8+ cytotoxic T lymphocytes,
has been reported to be associated with responses to neoadjuvant chemotherapy
and good clinical outcome in breast cancer [18, 33]. CD4+ CD25+ CD127- Treg
play a pivotal role in the control of immune responses [34, 35]. Treg normally
function to protect tissues from autoimmune diseases by suppressing self-reactive
cells, including CD8+ cytotoxic T lymphocytes, B cells and natural killer cells [36,
37, 38]. Additionally, they have an important role in the immunoediting process,
enabling the tumor to elude the host antitumor immune response, because of their
inhibiting action on cytotoxic activity of CD8+ and natural killer cells [36, 37].
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1.2.2 Characteristics of regulatory T cells
Treg represent a subpopulation of CD4+ lymphocytes that suppress the immune
response at different levels. Human peripheral blood CD4+ CD25+ forkhead	box
P3 (FoxP3)+ T cells, or Treg represent 4-8% of human CD4+ T cells [39]. They have
been characterized as suppressor T cells after the observation by Sakaguchi et al.
of induced organ-specific autoimmune disease in mice depleted for this particular
population [40].
The expression of CD25 (also known as IL-2 receptor-α) appears during the
transition of the CD4+ CD8+ T cell to the CD4+ CD8- T cell, therefore taking
part in normal thymocyte differentiation [41]. This reflects the activation of cells
during a process termed “altered negative selection”: future Treg probably express a
TCR with an intermediate affinity for self, to low for negative selection, but to high
to allow them to pass through to the periphery [42].
Minor differences are observed in respect to Treg population of “naturally occur-
ring”, which are the thymus derived cells naturally isolated from peripheral blood
and “induced”, generated in the lymph node. However, it is widely accepted that
they are both hyporesponsive and suppressive, as a result of the activation process,
acting via an APC-dependent mechanism [43]. Thus in normal process, Treg mod-
ulate immune responses through selective migration and accumulation at different
sites where regulation is required. Accumulative amount of data has demonstrated
the role in controlling Treg migration of distinct signals from chemokines/chemokine
receptors and integrins/integrin ligands in recruiting Treg in human pathologies and
for the homing of these cells, indispensable for them to acquire their full activation
state [44, 45]. In the mouse, direct evidences of roles for migration and functionality
played by chemokines and integrins was also shown in vitro and in vivo [46, 47].
1.2.3 Regulatory T cell markers
Despite the immunologists’ obsession to classify all immune cell types, the identifi-
cation of discriminatory cell-surface markers for the characterization and isolation
of Treg remains problematic. This could account for the sometime confusing re-
sults found in several Treg studies relative to their implication in cancer and is even
more surprising considering that we already dispose of a large panel of Treg mouse
markers. If traditionally, mouse and human Treg have been characterized as CD4+
CD25+, the purity of isolated human Treg remains an issue mainly because other
human T cells also upregulate CD25 when activated [48].
One significant advance in the study of mouse and human Treg has been the
identification of FoxP3 as key regulator of Treg development and function [49,
50]. Elegant mouse and human genetic studies demonstrated that mutation in the
FoxP3 gene were linked to the autoimmune manifestations observed in the scurfy
mouse that carry a spontaneous loss-of-function mutation or a deletion of FoxP3
and human immune dysregulations like polyendocrinopathy, enteropathy and X-
linked syndrome disease. But again, if it appears useful in mice, many activated
6
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Figure 1.2 – Regulatory T cell mechanisms of action according to Vignali et al.. Four basics mode
of action are here illustrated (a) via inhibitory cytokines, (b) via the cytolysis of targeted cells, (c) via
metabolic disruption and (d) via the inhibition of dendritic cells. TGF-β, transforming growth
factor-β; IL, interleukin, A2R, adenosine receptor; MHC, major histocompatibility complex.
non-regulatory human T cells transiently up-regulate FoxP3 under activation [48].
Moreover, FoxP3 is intracellular and could not serve routinely to Treg isolation so
that the search for specific surface markers has continued in earnest with the discov-
ery of the downregulation of CD127 (also known as IL-7 receptor) on Treg and the
90% correlation of the three membrane markers (i. e., CD4+, CD25+ and CD127-)
and FoxP3 expression [35].
Finally, it is possible that Treg, like other T cell populations, are composed of
heterogeneous subtypes, like suggested by Sakaguchi et al. [51]. They divided Treg
into three populations based on the expression of FoxP3 and CD45RO and showed
that these populations suppressed other cells via different mechanisms and not all
with the same intensity. Thus it appears probable that the search for better mem-
brane markers is not yet finished.
1.2.4 Regulatory T cell mechanisms of action
Defining how do these cells work is crucial to provide insight into the control pro-
cesses of peripheral tolerance and could also indicate potentially important thera-
peutic targets. Treg require TCR triggering to become fully functional, but once
activated they suppress T cells blindly, with no regard to the antigen specificity of
targeted cells [43].
Suppressive mechanisms used by Treg have been regrouped into four modes
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of action: (a) suppression by inhibitory cytokines, (b) suppression by cytolysis, (c)
suppression by metabolic disruption and (d) suppression by modulation of DC mat-
uration and/or function – Figure 1.2, p. 7 [52]. To date, it is difficult to say if Treg
functions are mediated by a single overriding suppressive mechanism or by multi-
ple, redundant or not, mechanisms. It is, however, more likely that Treg suppressive
functionality comes from multiple one, since none of the currently known mecha-
nisms seems to be exclusive. Again, the choice for suppression mechanism(s) to
use – dependent of the background, the context or the type of target cells – remains
unclear, underlying the need of more research in this domain.
Several studies already suggested that Treg infiltrated in tumors may adversely
affect prognosis via their immunosuppressive action. Increased tumoral Treg num-
ber have been correlated with poor OS in breast cancer, melanoma, lung carcinoma,
and hepatocellular carcinoma [14, 53, 54, 55]. Importantly, the high number of
Treg present in tumor environment raises the question of their recruitment.
1.3 Chemokines and their receptors
1.3.1 Discovery
The first description of directed, transendothelial leucocyte migration and accumu-
lation into organs in case of inflammation was made more than one century ago
by August Waller (1846) and Julius Cohnheim (1867). The first hypothesis, that
leucocytes could phagocytose bacteria and thus should have to migrate to inflamed
tissues, eventually in response to chemical agents, was postulated a couple of years
later by Ilja Metchnikoff (1891). But it took almost one century to have the first
in vitro demonstration of this phenomenon, when in the 60’s and 70’s the migra-
tion was observed via migration assays using the first chamber chemotaxis transwell
plates.
The next step was done in the 80’s, when several teams discovered and char-
acterized a new chemoattractant polypeptide named monocyte-derived	neutrophil
chemotactic	 factor (MDNCF) or neutrophil-activating	peptide (NAP). One year af-
ter, this chemokine was cloned, sequenced and renamed IL-8, first chemotactic
cytokine [56]. With help from sequence homologies and hybridization methods
other members of this new family were quickly identified. A few years later, on the
“3rd International Symposium on Chemotactic Cytokines” it was decided to rename
this cytokine subfamily after their chemotactic-cytokine effects into chemokine.
The list of chemoattractant quickly grew from C5a, through platelet	activating
factor (PAF) to the more than 50 chemokines or chemoattractants known today [3].
All these different chemoattractants were observed to bind to specific surface mem-
brane receptors, all members of the G protein-coupled	receptors (GPCR) family. In
the mean time, a lot of other signal polypeptides were discovered, with the result
that it soon began urgent to order all these new cytokines in subfamily and to give
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them an international nomenclature. Originally most of them were named with
different names, according to their different effects on cells.
1.3.2 Nomenclature
In 2000, a system of nomenclature was introduced in which each ligand and receptor
were respectively identified by its subfamily and given an identifying number. For
example, CCR4 refers to the chemokine receptor of the CC-family number 4, and
binds to CCL17 and CCL22 (chemokine ligand of the CC-family, number 17 and
22 respectively). Redundancy between different ligands and the same receptor or on
the contrary, between different receptors and the same ligand is considerable. If very
little is known about this lack of specificity, it may be an explanation for the quite
normal phenotypes of knockout (KO) mice for most inflammatory chemokines or
chemokine receptors unless challenged with inflammatory conditions or faced with
pathogens [57]. On the other hand, this redundancy could allow fine tuning of
immune responses, function of combination of ligands, receptors, but also other
molecules, possible oligomerization, glycosaminoglycans, etc.
CCL#, CXCL#, CL# and CX3CL# refer to the four families of chemokine
ligands. C stands for a cysteine and X for a non-cysteine amino acid, L for ligand,
and # denotes the identifying number. The larger chemokine family, composed by
the CCLs or β-chemokines, is characterized by two adjacent cysteines, near to the
N-terminal end of the protein –Table 1.1, p. 10. 27 chemokines have been reported
in this group, named CCL1 to CCL28 (CCL9 and CLL10 being the same one).
Notably a small number of them possess six cysteines: CCL1, CCL15, CCL21,
CCL23, CCL28.
In the second largest family, composed by the CXCLs or α-chemokines, the two
first cysteines are separated by one amino acid, represented in the name with an “X”
– Table 1.2, p. 11. 17 of them have been described, subdivided in two categories:
those with a specific amino acid sequence ELR (glutamic acid-leucine-arginine)
immediately before the first cysteine of the CXC motif, and those without.
XCL1 and XCL2 are the two chemokines characterized, in the third family,
the XCLs or γ-chemokines, and are characterized by only two cysteines: one N-
terminal cysteine and one cysteine downstream – Table 1.2, p. 11. These chemo-
kines are presumed to attract T cell precursors into the thymus [5].
Finally, CX3CL1 is the only chemokine discovered in the fourth family, CX3CL
or δ-chemokine – Table 1.2, p. 11. In the same fashion as for the CXC chemokines,
the two first cysteines are separated, in this case indeed, by three amino acids. It is
both secreted and tethered to the surface of the cell that expresses it, thereby serving
both as chemoattractant and as an adhesion molecule [3].
It is of importance to mention, that not all of these chemokines are present both
in mouse and human, underlying the difference between the two systems, but also
the functional redundancy of chemokines.
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Name Old name Produced Binds on Receptor(s)
CC (β)
CCL1 i I-309 M, T M, act.Th2 CCR8
CCL2 i MCP-1 M, Fib, En M, T, Ba, Fib CCR2,3
CCL3 i MIP-1α M, T, NK, N, DC, Fib, En M, T, DC CCR1,5
CCL4 i MIP-1β M, T, NK, N, DC, Fib, En M, DC CCR5
CCL5 i RANTES M, T, Fib, Epi, En, P, Eos M, T, DC, Eo CCR1,3,5
CCL7 i MCP-3 M, Fib, P M, T, NK, DC CCR1,2,3,5
CCL8 i MCP-2 N, Fib M, T, NK, Eo CCR2,3
CCL11 i Eotaxin-1 M, Eos, Fib, resp. Epi Eo, Ba, Th2 CCR3,5
CCL13 i MCP-4 M, L, En, Epi / Lung, Gut M, T, DC, Eo CCR2,3,5
CCL14 h HCC-1 S, G, Li, Mu M, Eo CCR1
CCL15 h HCC-2 L, NK, M, DC / Liver, Gut T, M, Eo CCR1,3
CCL16 h LEC M / Liver M, L CCR1
CCL17 m TARC T, DC / Thymus, Lung, Gut Thy, Th2 CCR4
CCL18 h PARC M, DC / Lung, LN, Thymus T CCR8
CCL19 h ELC DC / Thymus, LN T, B, DC, Thy CCR7
CCL20 m LARC Epi, M, DC, T / LN, Lung T,DC CCR6
CCL21 m SLC En / Thymus, Spleen, LN T, B, DC, Thy CCR7
CCL22 m MDC M, DC / Thymus, LN, Gut Th2, NK, DC CCR4
CCL23 i MPIF-1 DC / Pancreas, Muscle M, L CCR1
CCL24 i Eotaxin-2 M / Lung, Skin Eo, Ba, Th2 CCR3
CCL25 h TECK Epi, DC / Thymus, Liver, Gut Thy, T, M, DC CCR9
CCL26 i Eotaxin-3 Fib, En / Skin, Heart, Ovar Eo, Ba CCR3
CCL27 h CTACK Epi / Skin, Placenta T, Fib, En CCR10
CCL28 i MEC Epi / Brust, Colon T, Eo CCR3,10
i, pro-inflammatory; h, homeostatic; m, mixed function
Table 1.1 – Classification of human CC-chemokines. MCP-cluster in blue, MIP-cluster in red. B,
lymphocyte B; Ba, basophil; DC, dendritic cell; Eo, eosinophil; En, endothelium; Epi, epithelium;
Fib, fibroblast; Hep, hepatocyte; L, lymphocyte; M, monocyte/macrophage; N, neutrophil; NK,
natural killer cell; P, platelet; T, lymphocyte T; Th1/2, type 1/2 helper T cell; Thy, thymocyte; LN,
lymph node
1.3.3 Structure and classification of chemokine
Chemokines are small ligands, 70-130 amino acids and 8-12 kDalton (Da) proteins
(with the notable exception of CXCL16 and CX3CL1) that contain 1-3 (mostly
2) disulfides, with critical roles in cell migration during immune surveillance, in-
flammation and development. They interact with GPCR on target cells and cause
conformational changes that trigger intracellular signaling pathways involved in cell
movement and activation and are classified as chemokine based on shared structural
characteristics, small size and the presence of four cysteine residues (except for the
γ family and a few exceptions in the β family) in conserved locations that inter-
act with each other in pairs to create a Greek key shape that is a characteristic of
chemokines.
Although the sequence homology is highly variable, ranging from less than 20%
to over 90%, the tertiary structure is remarkably conserved – Figure 1.3, p. 12. This
tertiary structure always presents a disordered N-terminal of 6-10 amino acids func-
tioning as key signaling domain. The N-terminal has a critical role in receptor activa-
tion, and N-terminus truncations can render chemokines inactive or even able to act
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Name Old name Produced Binds on Receptor(s)
CXC (α)
CXCL1 i GRO-α M, Epi, En N, L, M, En CXCR2
CXCL2 i GRO-β M, Epi, En N, L, M, En CXCR2
CXCL3 i GRO-γ M, Epi, En N, L, M, En CXCR2
CXCL4 h PF-4 P Fib, En CXCR3
CXCL5 i ENA-78 M, N, Epi N CXCR1,2
CXCL6 i GCP-2 M, Fib / Heart, Lung, Kidney N CXCR2
CXCL7 i NAP-2 P, M, N N CXCR2
CXCL8 i IL-8 M, L, N, Fib, Epi N, T CXCR1,2
CXCL9 i Mig M, Fib, Hep, IFN / Spleen, Liver T, NK CXCR3
CXCL10 i IP-10 M, IFN / LN, Thy T, NK CXCR3
CXCL11 i I-TAC M, IFN / Spleen, Pancreas T CXCR3,7
CXCL12 h SDF-1 Fib / Spleen, Gut T, B, DC CXCR4,7
CXCL13 h BCA-1 DC, En / Spleen, LN, PeyerPatch B CXCR5
CXCL14 i BRAK all M, DC ?
CXCL16 i SR-PSOX DC / LN, Spleen, Lung T, NK, DC CXCR6
CXCL17 i DMC Stomach, Trachea D, M ?
C (γ)
XCL1 m Lympotactin T / Thymus, Spleen T, NK XCR1
XCL2 m MCP-1 T L XCR1
CX3C (δ)
CX3CL1 i Fractalkine En / Brain, Lung, Heart M, T, NK CX3CR1
i, pro-inflammatory; h, homeostatic; m, mixed function
Table 1.2 – Classification of all other human chemokines. GRO-cluster in green and IP-10-cluster
in yellow. B, lymphocyte B; DC, dendritic cell; En, endothelium; Epi, epithelium; Fib, fibroblast;
Hep, hepatocyte; IFN, IFN-γ stimulated cell; L, lymphocyte; M, monocyte/macrophage; N, neu-
trophil; NK, natural killer cell; P, platelet; T, lymphocyte T; Thy, thymocyte; LN, lymph node
as antagonists. Most of them are secreted from the cell, with two notable exceptions:
CX3CL1 and CXCL16, which also can stay on the extracellular cell membrane [3].
To produce directional migration signals for cell migration, concentration gradients
of chemokines must be formed, since cells exposed to a uniform concentration of a
chemokine move in random patterns rather than directionally. In vivo, the establish-
ment of a gradient is thought to involve binding to glycosaminoglycans; conditions
that could be mimiced in vitro by the chamber chemotaxis migration assay.
Chemokines can also be classified into three groups, according to their physi-
ological roles. Inflammatory chemokines are inducible in organs in processes like
immune response or inflammation (inflammation mediated by cytokines, bacterial
toxins, etc). They attract specialized leukocyte populations or subpopulations (e.g.,
neutrophil, monocyte, basophil, eosinophil, effector T cell, DC) to the inflamed lo-
calization and allow the immune system to respond various aggressions. They also
regulate the expression of genes in those cells, acting as transcription factor or via
stabilization of messenger	RNA (mRNA). The multitude of inflammatory chemo-
kines allows fine regulations of the immune response. This redundancy could be
explained, from an evolutionary point of view, by multiple gene duplications. There
are to date four clusters: MCP-cluster and MIP-cluster of the chromosome 17q11-
17q12, GRO-cluster of the chromosome 4q13 and IP-10-cluster of the chromo-
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Figure 1.3 – Schematic representation of the chemokine key functional regions. All chemokines
have a similar tertiary structure comprising a disordered N-terminal of 6-10 amino acids followed
by a long loop (known as the N loop), a 310 helix, a three-stranded beta-sheet, and finally a C-
terminal alpha helix.
some 4q21. These chemokines present highly conserved tertiary structures and act
mostly on the same receptor with a similar action. Homeostatic chemokines are
constituently expressed in the primary and secondary lymphoid organs and control
the migration and localization of T and B cells, as well as DC. This expression is
particularly important for the maturation of these cells and for the adaptive immune
response. Immune surveillance also involves migration of lymphocytes in response
to homeostatic chemokines. Certain chemokines are continuously expressed in tis-
sues such as the skin, intestinal mucosa, and lungs to promote constant monitoring
of these at-risk areas. Lastly, some chemokines are included in a third group, re-
flecting their mixed function, depending on the biological context or pathological
state. Expression of inducible chemokines is often triggered by inflammatory me-
diators such as tumor	necrosis	factor (TNF)-α, interferon (IFN)-γ, microbial products,
or trauma. These chemokines have roles in both innate and adaptive immunity in
12
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Figure 1.4 – Schematic representation of the chemokine receptor key functional regions. Muta-
genesis and chimeric receptor studies have identified regions of chemokine receptors important for
ligand binding, receptor activation, and internalization, although specific sequences involved in
signaling differ between different chemokine receptors.
response to infections, tissue damages, and other physiological abnormalities. Their
expression is temporary, until resolution of the situation.
1.3.4 Classification of chemokine receptors
The chemokine receptors are all class A GPCR, presenting three intracellular and
three extracellular hydrophilic loops – Figure 1.4, p. 13. They are commonly 340-
370 amino acids long and about 40 kDa proteins. The N-terminal domain is ex-
posed outside the cell and binds to chemokine(s). The C-terminal domain, con-
taining serine and threonine residues that act as phosphorylation sites, is coupled
with the G protein. Conserved extracellular cysteine disulphide bridges stabilize
the tertiary structure.
To date, 22 of them were described and since the “Gordon Research Conference
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Name Expressed on Ligand(s)
CXC receptor
CXCR1 N CXCL6, 8
CXCR2 alt N, En CXCL1, 2, 3, 5, 6, 7, 8
CXCR3 alt Th1 CXCL9, 10, 11
CXCR4 All CXCL12
CXCR5 B, T CXCL13
CXCR6 Th1, Tc1, NK CXCL16
CC receptor
CCR1 M, T, Eo, Ba CCL3, 5, 7, 14, 15, 16, 23
CCR2 alt M, Th1, DC, NK, Ba, Fib CCL2, 7, 8, 13
CCR3 Eo, Ba, Th2, P CCL2, 5, 7, 8, 11, 13, 15, 24, 26, 28
CCR4 M, Th2, DC, Ba CCL17, 22
CCR5 M, Th1, Tc1, NK CCL3, 4, 5, 7, 8, 11, 13
CCR6 alt T, B, DC CCL20
CCR7 T,DC CCL19, 21
CCR8 Th2, M, NK, DC CCL1
CCR9 alt T, IgA-Pla CCL25
CCR10 T CCL27, 28
C receptor
XCR1 T, NK, P, Thy XCL1, 2
CX3C receptor
CX3CR1 T, NK, M, En CX3CL1
Silent receptor
CXCR7 CXCL111, CXCL12, MIF
CCR11 alt CCL19, 21, 25
Duffy Ery, En CXCL1, 2, 3, 5, 6, 7, 8, 11
CCL2, 5, 7, 11, 13, 15, 17, 18, 22
D6 Placenta CCL2, 3, 4, 5, 7, 11, 13, 17, 22
alt, presence of alternative splicing(s)
Table 1.3 – Classification of all human chemokine receptors. B, lymphocyte B; Ba, basophil; DC,
dendritic cell; Eo, eosinophil; En, endothelium; Ery, erythrocyt; Fib, fibroblast; IgA-Pla, IgA+
plasmacell; M, monocyt/macrophage; N, neutrophil; NK, natural killer cell; P, platelet T, lympho-
cyte T; Tc1, type 1 killer T cell; Th1/2, type 1/2 helper T cell; Thy, thymocyte
on Chemotactic Cytokines” in 1996, divided into four families: CC chemokine
receptors, CXC chemokine receptors, one C chemokine receptor and one CX3C
chemokine receptor that correspond to the four distinct subfamilies of chemokines
they bind – Table 1.3, p. 14. In addition, chemokine receptors with structural fea-
tures that are inconsistent with a signaling function have been described. When
ligated, these “silent” (i.e., non-signaling) chemokine receptors do not elicit migra-
tion or conventional signaling responses, but instead damped the immune response
by binding, internalizing, and, in the case of D6, degrading chemokines – Table
1.3, p. 14. Chemokine decoy receptors recognize distinct and complementary sets
of ligands and are strategically expressed in different cellular contexts. The abil-
ity of chemokine receptors to signal upon ligand binding is due, at least in part,
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to the presence of a DRY (glutamic acid/aspartic acid-arginine-tyrosine) motif in
the second intracellular loop, which is missing in the scavenger receptors [58]. No
chemokine receptor structures have been solved to date, and models are generally
based on bovine rhodopsin, the only seven-transmembrane receptor for which three-
dimensional structures have been solved.
Chemokine binding on leukocytes leads to the rapid up-regulation of adhesion
molecules: integrins like very	late	antigen-4 (VLA-4) (or α4β1), which are needed
to bind more strongly epithelial cells or intercellular	adhesion	molecule (ICAM) and
vascular	cell	adhesion	molecule (VCAM) (both overexpressed in response to proin-
flammatory cytokines like IL-1, TNF-α or IFN-γ). Lastly, chemokine binding
induced reorganization of the cytoskeletal, which finally leads to the cell polariza-
tion, migration and infiltration of activated leukocytes.
1.4 Goals of this work
1.4.1 Epidemiology of gynecological tumors
Breast cancer is a heterogeneous disease embracing a range of biologic behaviors
and prognostic characteristics [59]. Worldwide, breast cancer is the most common
invasive cancer in women, representing 23% of all cancers diagnosed in women in
2008 [60]. The same year, breast cancer resulted in 1.38 million diagnosed cases and
458,000 deaths [60]. During the last decades, early diagnosis and multiple therapies
helped to improve survival rate. Survival rates in the developed world are high,
between 80% and 90% of the women being alive 5 years after the first diagnosis [59,
60]. But since the 1970s, the number of case has significantly increased, possibly
due to modern living style, better diagnostic or longer lifetime. In addition, the
situation in the developing countries remains problematic [61].
Among gynecological tumors, ovarian cancer has the highest mortality rate.
Worldwide, over 200,000 women are diagnosed with primary ovarian cancer every
year [62]. These cancers are mostly diagnosed at a late stage, over 75% of patients
are already presenting metastasis at first diagnosis. Overall five-year survival rate
ranges between devastating 25% and 49% [63]. Although standard therapy initially
leads to good response rates, the disease recurs in over 50% of the cases within the
following five years [64]. The rate of ovarian cancer between 1993 and 2008 de-
creased in women of the 40-49 age cohort and in the 50-64 age cohort, possibly
due to this group’s widespread adoption of oral contraceptives [62].
1.4.2 Current problematic
Current therapeutics often fail to eliminate all tumor cells and tumors with reduced
immunogenicity may escape after a period of equilibrium due to a process called
immunoediting [31, 65]. This concept holds that the immune system not only pro-
tects the host against development of primary nonviral cancers but also sculpts tu-
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mor immunogenicity [66]. Limitations of current therapies have led to increasing
enthusiasm for defining new prognostic tools and highly targeted therapies.
1.4.3 Working hypothesis
During the last decade, three chemokine receptors (i.e., CCR4, CCR8, and CCR10)
were found to be specifically expressed on Treg. With their respective associated
chemokines, they all play a pivotal role in Treg migration. CCR4 and CCR8 were
the first receptors to be described on Treg [67]. Together with CCL22, the ligand
for CCR4, they lead to Treg migration into tumors as described in ovarian can-
cer [15]. CXCR4 and CCR7 were also found expressed on Treg, although not spe-
cifically [44, 45]. Bone marrow strongly expresses CXCL12, the ligand for CXCR4,
leading to human Treg traffic and accumulation. The CCR7 pathway is very impor-
tant for the Treg migration into lymph nodes and the acquisition of their full sup-
pressive functions. More recently CCR10 was found overexpressed on Treg [16].
In a tumors hypoxia context, it was shown that CCL28 promotes tumor tolerance
in a Treg dependent mechanism.
1.4.4 Purpose of this work
Although previous studies associated increased intratumoral number of CD4+ CD25+
Treg with CCL22 and CCL28 and reported adversely affected prognosis in ovarian
cancer, before our current work the clinical importance of other chemokines was
unknown [15, 16]. Since several other chemokines were described to be potentially
responsible for Treg accumulation in tumors and therefore, represent potential tar-
gets for cancer therapy, we aimed to investigate whether other chemokines could
lead to specific migration of Treg. The purpose of this work was to assess the clini-
cal significance of different Treg attracting chemokine intratumoral expressions in
breast cancer and ovarian cancer patients with long-term follow-up. Thus, we here
investigated the prespecified hypothesis that the expression of Treg specific chemo-
kines in cancer tissue predicts the OS and could therefore be used as biomarkers or
as targets for immunotherapy.
*
* *
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— Anything	found	to	be	true	of	E.	coli	must	also	be	true	for	elephants.
Jacques	Monod, molecular	biologist, 1954
2.1 Lymphocyte acquisition and manipulation
2.1.1 Peripheral blood mononuclear cell isolation
Human peripheral	blood	mononuclear	cells (PBMC) were purified from healthydonor peripheral blood by Biocoll (Merck, Darmstadt, Germany) density gra-
dient centrifugation. All samples were collected in the laboratory and were extempo-
raneously performed. Briefly, peripheral blood was two times diluted in phosphate-
buffered	saline (PBS) (GE Healthcare, Munich, Germany) and 30 mL were then care-
fully set down on 15 mL Biocoll solution in a 50 mL tube. Tubes were centrifuged
at 1000 g, 4°C for 20 minutes, without centrifugal brake. The formed PBMC ring
was quickly removed in order to minimize interaction with Biocoll and cells were
washed three times in PBS.
2.1.2 Lymphocyte maintenance and culture
Cells were then maintained in Roswell	Park	Memorial	Institute	medium (RPMI) 1640
(Merck, Darmstadt, Germany) with 10% heat-inactivated fetal calf serum, 2 mmo-
lar (M) L-glutamine, 1 mM sodium pyruvate, 1% nonessential amino acids, 100
international	unit (IU)/mL penicillin, 100 mg/mL streptomycin and 0.05 mM β-
mercaptoethanol supplemented with 10 ng/mL IL-2 (i.e., 180 IU/mL) (all from
Life	Technologies, Paisley, United Kingdom). PBMC were set up for migration
assays as soon as possible and were never kept in RPMI more than 12 hours.
17
2. Materials and Methods
2.1.3 Migration assay
Chemotaxis assays were performed using 3 µm pore polycarbonate filters in a 96-
well transwell chamber (Corning, New York, USA). Total PBMC (106 cells/well),
after being washed three times with PBS, were added in migration medium (RPMI
1640 supplemented with 0.5% bovine serum albumin and 10 ng/mL IL-2) on the
top chamber. Different concentrations of chemokines (all from Peprotech, Ham-
burg, Germany) were added in the same medium supplemented on IL-2 to the
lower well. All experiments were made at least in triplicate and migration occurred
during three hours at 37°C and 5% CO2. Cells migrated into the lower chamber
were then washed and labeled with antibodies before being analyzed by flow cytom-
etry.
Total migrated cells were counted using CountBright absolute counting beads
(Life	 Technologies, Paisley, United Kingdom). Migration results are shown as
chemotaxis	 index (CI), which represents the total number of migrated cells in re-
sponse to a chemokine divided by the total number of migrated cells without che-
mokine. The enrichment	factor (EF) was obtained dividing the initial percentage of
cells by the final percentage of cells and adding 1.
2.1.4 Flow cytometry analysis
PBMC migration was analyzed using the BD FACS Canto	 II cytometer (BD Bio-
sciences, Heidelberg, Germany). Antibodies (anti-CD4 PacBlue, anti-CD25 APC
and anti-CD127 PE, all from Biolegend, San Diego, USA) were added to the dif-
ferent cell populations and incubated for 20 minutes at 4°C in the dark, before being
washed with PBS and analyzed. Gates were set according to side scatter and forward
scatter on the lymphocyte population before gating on CD4+ CD25high CD127low
cells – Figure 2.1, p. 19. CD4+ CD25high CD127low labeling shows 90% correla-
tion with FoxP3 expression [35]. The percentage of positive cells of each individual
marker were calculated using FlowJo (FlowJo, Ashland, USA).
2.2 Chemokine receptor mRNA level expressions
2.2.1 Cell sorting
Isolation of the CD4+ CD25high CD127low population was performed in a two-
steps procedure directly from the freshly isolated PBMC using a CD4+ CD25high
CD127low Treg isolation kit (Miltenyi	Biotec, Bergisch Gladbach, Germany). The
non-CD4+ CD127high cells were first magnetically labeled with a cocktail of biotin-
conjugated antibodies and secondary anti-biotin monoclonal antibodies. Labeled
cells were depleted from the total population by separation over a MACS LD column
placed in the magnetic field of a MACS separator.
During the second step, the CD4+ CD25high CD127low Treg were directly la-
beled among the CD4+ CD127low enriched population with CD25high micro-beads
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Figure 2.1 – Gates were set according to side scatter and forward scatter on the lymphocyte popu-
lation before gating on CD4+ CD25high CD127low cells (red square).
and isolated by positive selection from the pre-enriched fraction by separation over
a MACS MS column placed in the magnetic field of a MACS separator. During the
separation, cells were kept cold, and all solutions were pre-cooled in order to prevent
capping of antibodies on the cell surface and non-specific labeling. Cells were re-
suspended in a buffer made from PBS, 0,5% bovine	serum	albumin (BSA) and 2mM
ethylenediaminetetraacetic	acid (EDTA). Antibodies were added as recommended by
the fabricant and incubated 15 minutes at 4°C in the dark. Cells were three times
washed before magnetic separation and then rapidly further performed.
2.2.2 mRNA isolation
After isolation cells were washed three times with pre-cooled PBS. Total cellular
ribonucleic	acid (RNA) was extracted from the different cell populations using the
QuickGene	RNA blood	cell	kit	S and the QuickGene	mini	80 automat (Fuji, Tokyo,
Japan). Briefly, leukocyte pellets were pooled down in 1.5 mL tubes, resuspended in
520 µL of LRB (after reconstitution with adequate volume of β-mercaptoethanol)
and thoroughly mixed by vortexing for 30 secondes. Finally, 250 µL of 99% ethanol
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Receptor Forward Reverse Sonde
CCR1 5’-TCTGACTCTTGGCACAGCAT-3’ 5’-GCCACCATTACATTCCCTCTC-3’ #76
CCR2 5’-TGAGACAAGCCACAAGCTGA-3’ 5’-TTCTGATAAACCGAGAACGAGAT-3’ #56
CCR3 5’-TGCAGTGCTCTTTACCCAGA-3’ 5’-GGTCATTCTCAGAGTGTGGAAA-3’ #78
CCR4 5’-TTCGTGTTTTCCCTCCCTTT-3’ 5’-ACCTAGCCCAAAAACCCACT-3’ #84
CCR5 5’-AACCAGGCGAGAGACTTCTCA-3’ 5’-GATCCAACTCAAATTCCTTCTCA-3’ #14
CCR6 5’-AAAGGCATCTATGCCATCAACT-3’ 5’-GTACCGGTCCATGCTAATGC-3’ #68
CCR7 5’-GGGGAAACCAATGAAAAGC-3’ 5’-ACCTCATCTTGACACAGGCATA-3’ #77
CCR8 5’-TGCCTCCTGTTTGTATTCAGTCT-3’ 5’-CAGACCACAAGGACCAGGAT-3’ #64
CCR9 5’-CACCATGACACCCACAGACT-3’ 5’-TCACAGTAGAAGTCAGTGAAGTTGAA-3’ #21
CCR10 5’-AGTAGGTGGGGGAACACTGA-3’ 5’-GCAAGGCACAGAGGTAGTCC-3’ #34
CCR11 5’-TGCAAATGAGAAAAACACTAAGGT-3’ 5’-TGGCAAAAACAAGCTTGAAA-3’ #32
Table 2.1 – Primers used for the qPCR analysis. All primers were designed using the Roche	assay
design	center – #number corresponds to probe from the Universal	Probe	Library.
was added to each tube. Tubes were thoroughly mixed by vortexing for 30 secondes
and kept at 25°C for 5 minutes. After a flash spin-down, whole lysate were trans-
ferred to the cartridge and performed for one minute under pressure. Cartridges
were washed three times with 750 µL WRB solution (after reconstitution with ad-
equate volume of ethanol). Elution was performed in RNAse-free water for one
minute under pressure after waiting for 30 secondes at 25°C. Total RNA concentra-
tion and purity was determined with aNanodrop (Thermo	Fisher	Scientific, Waltham,
USA). 260 nm absorption was compared with 280 nm absorption and the ratio op-
tical	density (OD)260 nm/OD280 nm was routinely ≥2. If not immediately used,
total RNA was stored at -20°C.
2.2.3 cDNA transcription
complementary	DNA (cDNA) from total mRNA was synthetized using the Fermentas
RT-kit and oligo(dT) primers (Fermentas, Waltham, USA). Briefly, up to 1 µg of total
RNA was mixed with 2 µL 10X reaction buffer, 1 µL oligo(dT) primers, 2 µL 10
nM dNTP mix and completed to 20 µL with nuclease-free water in polymerase
chain	reaction (PCR) tubes. Oligo(dT) primes cDNA synthesis from the poly(A)
tail present at the 3’-end of eukaryotic mRNA and thus allow to obtain a copy
from all mRNA previously isolated. PCR tubes were placed in a thermal cycler and
warmed at 37°C for 30 minutes to allow the transcription and 10 minutes at 72°C
to terminate every reaction before cooling down to 4°C. Total cDNA concentration
and purity was determined with a Nanodrop (Thermo	Fisher	Scientific, Waltham,
USA). 260 nm absorption was compared with 280 nm absorption and the ratio
OD260 nm/OD280 nm was routinely ≥1.8. If not immediately used, total cDNA
was stored at -20°C.
2.2.4 RT-qPCR analysis
The following synthetic primers (all Eurofins	Scientific, Luxembourg, Luxembourg)
were used for the real-time	PCR (qPCR) (designed using the Roche	assay	design	center
– #number correspond to probe from the Universal	ProbeLibrary) – Table 2.1, p. 20.
The qPCR reactions were performed in optical	96-well	LightCyler	480	Multiwell	Plate
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using the LightCylcer	480 (Roche, Basel, Switzerland). Reaction were performed in
the following mix (per well): water 3 µL, sonde 0.2 µL, primers 0.4 µL + 0.4 µL
(forward and reverse), master mix 5 µL (VWR International, Radnor, USA) and
cDNA 2 µL. Quantity values generated for gene expression were obtained by com-
parison of the fluorescence generated by each sample with hypoxanthine-guanine
phosphoribosyltransferase (HPRT) standard curves. As control of Treg purity, the
level of FoxP3 and CD127 mRNA was quantified in isolated cell populations. As
control of RNA isolation purity, qPCR were performed with 2 µL from isolated
RNA solutions.
2.3 Histopathology
2.3.1 Breast cancer patient recruitment
Microarrayed tissue samples from breast cancers were used in this retrospective
study. Samples were collected from patients undergoing surgery at the Gynecology
unit (Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-
Universität, Munich).
All cases had been previously characterized in terms of histology (nodal status,
tumor size, grade, estrogen	receptor (ER)-α/progesteron	receptor (PgR)-α/human	epi-
dermal	growth	factor	receptor	2 (Her2) status at the Instituty of Pathology, Ludwig-
Maximilians-Universität, Munich. The histological classification was determined
according to a modification of the Elston and Ellis grading proposed by Bloom and
Richardson (Elston and Ellis, 1991). The hormone receptor status was evaluated
by immunohistochemistry. The tumor was classified as hormone receptor positive
in case of positive staining in ≥ 10% of the tumor. Normal breast tissue was ob-
tained from women undergoing breast reduction surgery (n= 7). Criteria for the
selection of patients for the tissue microarray were adequate routinely fixed biopsy
material, no history of previous malignancy but history of distant metastases during
the course of the disease.
A total of 180 ductal tumors, 14 lobular tumors and 5 others were used for this
study. No preselection of patients was made. All available patients suitable for the
inclusion were selected. Patients were not matched for stage disease or age. Patients
were diagnosed from 1986 to 2007 and almost all underwent surgery within one
month (max 7 months). All patients received standards surgical treatment of either
mastectomy or wide local excision with radiotherapy. Systemic adjuvant treatments
were given based on clinical scores and hormone receptor status. The end of the
follow-up period was October 2014. Additional patient information is listed in –
Table 3.3, 3.4, and3.5, pp. 37, 38, 39. Of the 199 tumors on the array, 192 presented
an assessable FoxP3 staining, 193 an assessable CCL1 staining, 194 an assessable
CCL22 straining, and 192 an assessable CCL27 staining.
All materials was sampled for diagnostic purposes and research was done in
accordance with the legal requirements concerning confidential medical commu-
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nication as well as the data protection act. Consequently, consulting the ethics
committee of the medical school, Ludwig-Maximilians-Universität, Munich, and
written informed consent from the patients prior to participation in the study was
not required.
2.3.2 Ovarian cancer patient recruitment
203 tumor tissue samples were selected from the archives of the Institute of Pathol-
ogy of the Ludwig-Maximilians-Universität, Munich for this study. All patients
had undergone debulking surgery at the Klinik und Poliklinik für Frauenheilkunde
und Geburtshilfe, Munich, and had been previously characterized in terms of histol-
ogy at the Institute of Pathology of the Ludwig-Maximilian-Universität, Munich.
The patients were between 27 and 87 years of age at diagnosis, with a median
age of 60. tumors were graded according to the Silverberg grading system. Most
tumors were graded class 3+4 (62.2%) and only very few class 1 (2.96%). Only
samples classified as stage III cancers, according to the International	Federation	of
Gynecology	and	Obstetrics (FIGO), were included. All histological types of epithelial
ovarian carcinoma were selected, but the serous (77.1%), endometroid (8.1%) and
adenocarcinoma NOS (5.3%) were by far the most commonly represented types.
Selection criteria of patients for the inclusion in this study were previous inclusion
and remain of adequate routinely fixed biopsy material (203 of the total 210 orig-
inally included patients) [68]. Additional patient information is listed in – Table
3.1 and 3.2, pp. 33, 34. Of the 203 tumors, 203 presented an assessable CCL1
staining.
All materials was sampled for diagnostic purposes and research was done in
accordance with the legal requirements concerning confidential medical commu-
nication as well as the data protection act. Consequently, consulting the ethics
committee of the medical school, Ludwig-Maximilians-Universität, Munich, and
written informed consent from the patients prior to participation in the study was
not required.
2.3.3 Immunohistochemistry
Paraffin wax-embedded tissue slide samples were deparaffinized in xylol for 20 min-
utes, washed in 100% ethanol and then incubated in methanol/H2O2 (3%) for 20
minutes. After rehydration in an alcohol gradient to distilled water, the slides were
placed in a pressure cooker containing sodium citrate buffer (pH= 6.0) and cooked
for 5 minutes. Slides were washed twice in PBS and blocked using blocking solution
1 from ZytoChem	Plus horseradish	peroxidase (HRP) Polymer Kit (Zytomed, Berlin,
Germany) for 5 minutes. Each slide was separately incubated with a polyclonal
rabbit anti-human CCL1 primary antibody (Atlas	antibodies, Stockholm, Sweden)
diluted 1/200 in PBS, a polyclonal rabbit anti-human CCL22 primary antibody
(Peprotech, Hamburg, Germany) diluted 1/200 in PBS, a polyclonal rabbit anti-
human CCL27 primary antibody (Atlas	antibodies, Stockholm, Sweden) diluted
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1/200 in PBS or a monoclonal mouse anti-human FoxP3 primary antibody (clone
236A/E7) (Abcam, Cambridge, USA) diluted 1/300 in PBS. Incubation of the sec-
tions with the primary antibodies lasted for 16 h at 4°C. Afterward, sections were
washed twice in PBS before incubation with postblock reagent 2 (Zytomed, Berlin,
Germany) for 20 minutes. The slides were then washed in PBS and then incubated
with the HRP-polymer 3, containing secondary antibody coupled with detection
enzyme (Zytomed, Berlin, Germany) for 30 minutes. Staining was performed us-
ing 3,3-diaminobenzidine (DAB)-substrate solution (Dako, Glostrup, Denmark) for
180 seconds. Counterstaining was carried out with Mayer’s hemalaun for 2 minutes.
Finally, sections were washed in tap water for 5 minutes and afterwards dehydrated
in an ascending alcohol serie and washed in xylol. Slides were cover-slipped with
Eukittquick-hardening mounting medium (Sigma-Aldrich, St. Louis, USA).
2.3.4 Quantification of immunohistochemistry
For each labelling, absolute numbers of positive cells were computer-aided deter-
mined. Without any knowledge of identity, pictures were systematically taken (ar-
rays contained duplicate cores) and positive cells were automatically counted using
the image	J software (Version 1.49o, National Institutes of Health, Bethesda, USA).
DAB labelling was extracted using the IHC Toolbox plugin and cells were then de-
fined and counted based on their size and morphology – Figure 2.2, p. 24.
2.4 Statistical analysis
2.4.1 Statistical program
The statistical program R (Version 0.99.441, RStudio, Inc., Boston, USA) was used
for data collection and processing as well as analysis of statistical data. Following
packages were used:
• U. Ligges and M. Mächler (2003). Scatterplot3d - an R Package for Visual-
izing Multivariate Data. Journal of Statistical Software 8(11), 1-20.
http://www.jstatsoft.org.
• R Core Team (2015). R: A language and environment for statistical comput-
ing. R Foundation for Statistical Computing, Vienna, Austria.
http://www.R-project.org/.
• T. Therneau (2015). A Package for Survival Analysis in S. version 2.38.
http://CRAN.R-project.org/package=survival.
• H. Wickham (2009). ggplot2: elegant graphics for data analysis.
http://had.co.nz/ggplot2/book.
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Figure 2.2 – Representative examples of computer-aided determined labelings. (a-b) Whole
breast cancer tissue section with CCL1 recognition. (c-d) Whole breast cancer tissue section with
CCL22 recognition. (e-f ) Whole breast cancer tissue section with CCL27 recognition. (g-h)
Whole breast cancer tissue section with FoxP3 recognition. All magnifications × 200.
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2.4.2 Statistical tests
The Kruskal-Wallis test was used to compare more than two independent groups,
and the Mann-Whitney U-test was used for evaluation of two independent groups.
These tests are one-way analysis of variance and analyze two or more samples which
are independent from each other. Contingency tables were analyzed using the Pear-
son’s χ2 test. Linear regression were realize using the Pearson’s product-moment
correlation or Spearman’s Rs based on the continuity of analyzed values. The choice
between interquartile	range (IQR) or standard	error	of	the	mean (SEM) is detailed in
the relevant figure legends. Patients included in the statistical models are those for
which all the necessary data was available. A small number of patients did not have
complete data. Values with p≤ 0.05 were considered statistically significant.
2.4.3 Survival analysis
Given that there is no clinical defined cutoff point for the number of chemokine-
expressing cells in such a context, we always selected a cutoff at the median values
because this divided the patients into equal-sized groups, and does not make the
assumption of an artificial cutoff for statistical analyses. We systematically analysed
whether there was any correlation between cell numbers and age, nodal status, tu-
mor size, tumor rest, grade, ER-α/PgR-α/Her2 status, adjuvant therapy, and OS.
Survival was measured from the date of diagnosis to the time of death or the time
the patients was last seen. The log-rank test was used to perform univariate analyses
and the survival curves were estimated by the Kaplan-Meier (KM) method. Prognos-
tic factors for survival were evaluated in multivariate analyses by Cox proportional
hazards regression. The statistical tests are detailed in the relevant figure legends.
2.4.4 Kaplan-Meier curves with ggplot2
Unfortunately, the ggplot2 package does not accept a survfit object for representa-
tion of KM curves. In order to plot the curves with this package, following code
was modified and used in this work:
#####################################
##### P lo t t ing KM using ggplot2 #####
#####################################
# Define funct ion
ggkm <− func t ion ( s f i t , r e t u rn s = FALSE,
x l ab s = ”Time a f t e r Surgery (Months ) ” , y l ab s = ”
Proport ion Surv iv ing ” ,
y s t r a t a l a b s = NULL, ystrataname = NULL,
timeby = 50 , main = ” Overa l l Su r v i v a l ” ,
pva l = TRUE, . . . ) {
# Arguments and theme
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i f ( i s . nu l l ( y s t r a t a l a b s ) ) {
y s t r a t a l a b s <− as . cha r a c t e r ( l e v e l s ( summary ( s f i t ) $ s t r a t a ) )
}
m <− max( nchar ( y s t r a t a l a b s ) )
i f ( i s . nu l l ( ys t rataname ) ) ystrataname <− ” ”
t imes <− seq (0 , max( s f i t $time ) , by = timeby )
. df <− data . frame ( time = s f i t $time , n . r i s k = s f i t $n . r i sk , n . event =
s f i t $n . event , surv = s f i t $ surv , s t r a t a = summary ( s f i t , censored =
T)$ s t r a t a , upper = s f i t $upper , lower = s f i t $ lower )
l e v e l s ( . df$ s t r a t a ) <− y s t r a t a l a b s
ze ros <− data . frame ( time = 0 , surv = 1 , s t r a t a = f a c t o r ( y s t r a t a l a b s ,
l e v e l s = l e v e l s ( . df$ s t r a t a ) ) , upper = 1 , lower = 1)
. df <− rbind . f i l l ( zeros , . df )
d <− l ength ( l e v e l s ( . df$ s t r a t a ) )
p <− ggplot ( . df , aes ( time , surv , group = s t r a t a ) ) +
geom_ step ( aes ( co lour = s t r a t a ) , s i z e = . 7 ) +
s c a l e _ co lour _manual ( v a l u e s = c ( ” darkred ” , ” b lack ” ) ) +
theme_minimal ( ) +
theme ( a x i s . t i t l e . x = element_ t e x t ( v j u s t = . 5 ) ) +
s c a l e _x_continuous ( x labs , breaks = times , l im i t s = c (0 , max( s f i t $
time ) ) ) +
s c a l e _y_continuous ( y labs , l im i t s = c (0 , 1) ) +
theme ( panel . g r id . minor = element_blank ( ) ) +
theme ( legend . po s i t i on = c ( .83 , . 86 ) ) +
theme ( legend . key = element_ r e c t ( co lour = NA) ) +
theme ( legend . t i t l e = element_ t e x t ( co lour = ” white ” ) ) +
l ab s ( l i n e t yp e = ystrataname ) +
theme ( p lo t . margin = uni t ( c (0 , 1 , . 5 , i f e l s e (m < 10 , 1 .5 , 2 .5 ) ) , ”
l i n e s ” ) ) +
g g t i t l e (main )
# Plot the curve s
p r i n t (p )
i f ( r e tu rn s ) r e tu rn (p )
}
Listing – Code adjustments made to plot KM curves using the ggplot2 package in R. Takes a
survfit object as argument.
*
* *
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— In	God	we	trust, all	others	bring	data.
William	E.	Deming, engineer	and	statistician, date	uncertain
3.1 Chemokine screening
3.1.1 Screening among the CC-chemokine family
Knowing that the mechanism of immunosuppression requires Treg to have closecontact with target cells and that Treg use specific chemokine receptors to lo-
calize into tumors, we decided to study the clinical significance of the different Treg
attracting chemokines. During the last decade, several chemokines were described
to specifically attract Treg. But to our knowledge, no screening of an entire chemo-
kine family was ever done. We therefore analyzed the migration of CD4+ T cell
populations in response to a panel of all CC chemokines – Figure 3.1, p. 28. Anal-
ysis of the CI after migration in response to a single dose of 250 ng/mL revealed
that 13 out of 25 chemokines (i.e., CCL1, 2, 3, 5, 7, 8, 17, 19, 20, 21, 22, 23, and
CCL27) significantly attract CD4+ T cells. Notably, CCL19 induced such a strong
migration (median CI, 5.88 and 14.14, Treg and conventional	T cells (Tcon), respec-
tively), that it only partially appears on the top of the Figure 3.1, p. 28 for the sake
of visibility. Other chemokines seem, at least in our settings and for the 250 ng/mL
tested dose, not to induce migration of the CD4+ T cells.
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Figure 3.1 – Chemotactic response profile of human CD4+ CD25low Tcon and CD4+ CD25high
CD127low Treg in response to all CC-chemokines (250 ng/mL). Median and IQR of four exper-
iments performed in triplicate. Red dotted bar set at 1, no migration.
Figure 3.2 – Enrichment after migration of human CD4+ CD25high CD127low Treg among the
CD4+ T cell population in response to all CC chemokines (250 ng/mL). Light orange, significantly
more Tcon after migration; dark orange, significantly more Treg after migration; white, no change.
Median and IQR of four experiments performed in triplicate. Mann-Whitney U test. ***P< 0.001.
Red dotted bar set at 1, no enrichment.
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3.1.2 CCL1, CCL22 and CCL27 specifically attract regulatory T
cells
We reasoned that Treg could use particular chemokine receptors to specifically ac-
cumulate in the tumors. Work done previously on Treg migration described pref-
erential or specific migration in response to chemokines binding on specific recep-
tors. To determine the migration specificity, we calculate the EF among the CD4+
T cell population for the same migration – Figure 3.2, p. 28. EF was calculated
based on Treg ratio before and after migration for all chemokines and set at 1 for
no migration. As it clearly appears, only CCL1, CCL22 and CCL27 were able to
significantly cause a Treg enrichment after migration in response to a single dose of
250 ng/mL. Most other chemokines caused impoverishment of the Treg population
(i.e., CCL2, 3, 5, 7, 8, 11, 13, 15, 18, 19, 20, 21, 22, 23, 25, 26, and CCL28). A
few chemokines, mostly those not inducing any significant migration, do not cause
neither enrichment nor impoverishment among the CD4+ T cell populations.
3.1.3 Internal control and validation of our targets
We also analyzed all chemokine receptor mRNA expression levels and compare
Tcon and Treg expression levels. To determine cell population differential expres-
sions, we normalized our data against chemokine receptor expression levels in the
CD4- population – Figure 3.4, p. 30. Importantly, CD127 mRNA level was higher
in the Tcon population, whereas FoxP3 mRNA level was higher in the Treg pop-
ulation. As expected, significantly higher mRNA expression levels for chemokine
receptors binding to CCL1, CCL22 and CCL27 (i.e., CCR4, CCR8 and CCR10)
were observed among the isolated Treg population.
Finally, to support the idea that these chemokines were indeed responsible for
the observed cell migrations and to control the quality of our migration assays, we
took advantage of the shortened version of CCL22 (67 amino acid instead of 69
amino acid), which binds to its receptor CCR4, but does not induce migration.
Consistent with this the shortened version of CCL22, noted CCLneg on the fig-
ure 3.1, p. 28 and the figure 3.2, p. 28 induced neither significant migration nor
significant enrichment of cells among the CD4+ T cell population. Migrations in
response to CCL1, CCL22 and CCL27 were reproduced using the suboptimal dose
of 50 ng/mL and a dose of 500 ng/mL – Figure 3.3, p. 30. We observed the typical
dose/response effect for all three chemokines. CCL1 and CCL22 are causing much
more chemotaxis than CCL27. But CCL27 leads to a very stable migration, not
decreased by the chemokine receptor desensibilisation process, even for the highest
dose of 500 ng/mL.
Both migration and enrichment are required for Treg accumulation, like in a
tumor microenvironment. Overall, our results suggest that CCL1, CCL22 and
CCL27 might be the best candidates.
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Figure 3.3 – Chemotactic responses of Treg to CCL1, CCL22 and CCL27, respectively. Mean
and SEM of three experiments performed in triplicate. Mann-Whitney U test. ***P< 0.001. Red
dotted bar set at 1, no migration.
Figure 3.4 – CC Chemokine receptor differential mRNA expression levels. All values were nor-
malized against chemokine receptor expression levels in the CD4- population. Median and IQR
of three experiments performed in dupicate. Mann-Whitney U test. *P< 0.05; **P< 0.005. Red
dotted bar set at 1, level in the CD4- population.
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3.2 Expression of chemokines in ovarian cancer
3.2.1 First description of CCL1 expression in ovarian cancer
As can be seen in representative photomicrographs, ovarian cancer tumor sections
expressed CCL1 – Figure 3.5, p. 31. Assessment of all tissue microarray sections
showed a high degree of variability in chemokine-expressing cell total numbers.
CCL1 was expressed intratumorally by tumor cells (median, 150 cells/mm2; range,
0 to 2064) and peritumorally by immune cells (median, 169 cells/mm2; range, 0
to 1900). In both cases expression in normal ovarian tissue was significantly lower
than in tumor tissues (p= 0.028 and p= 0.024 intratumorally and peritumorally, re-
spectively) – Figure 3.6, p. 32. Although there was a degree of variability in intra-
and peritumoral CCL1-expressing cell total numbers, both expressions showed a
correlation in ovarian cancer (p= 2.38 10-07, ρ= 0.353, Pearson’s product-moment
correlation) – Figure 3.7, p. 32.
Figure 3.5 – Representative examples of CCL1 immuno-staining in ovarian cancer. (a) Whole
ovarian cancer tissue section with few CCL1-expressing tumor cells. (b) Whole ovarian cancer
tissue section with numerous CCL1-expressing tumor cells. (c) Whole ovarian cancer tissue section
with few CCL1-expressing immune cells. (d) Whole ovarian cancer tissue section with numerous
CCL1-expressing immune cells. (a-b-c-d) magnification × 200.
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Figure 3.6 – Total number of CCL1-expressing cells in normal ovarian tissue compared to ovar-
ian tumor tissues. Median and IQR of CCL1 cell numbers. Mann-Whitney U test. *P< 0.05.
Figure 3.7 – Linear regression representing the relation between intra- and peritumoral CCL1
expression in ovarian tumor tissues. Linear regression line in red with the 95% confidence region
in light grey.
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CCL1+ ≤ 150† CCL1+ > 150†
Variable No. % No. % Significance
Total No. of patients 100 49 103 51
Age, years p= 0.532
≤ 60 49 24 56 28
> 60 51 25 47 23
Histological subtype p= 0.359
Serous 77 39 81 40 Rs= 0.065
Mucinous 2 1 0 0
Endometroid 10 5 6 3
Adenocarcinoma (NOS) 5 2 5 2
Undifferentiated 4 2 3 2
Unknown 5 2 5 2
Grade p= 0.372
I 4 2 2 1 Rs= -0.064
II 28 14 39 19
III & IV 64 31 60 30
Unknown 4 2 2 1
Optimal surgical debulking p= 0.136
Radical operation 24 12 25 12 Rs= 0.105
Remaining tumor ≤ 2 cm 37 18 28 13
Remaining tumor > 2 cm 23 11 19 10
Sample laparotomy 1 1 1 1
Unknown 18 9 27 13
OS, 15 years Worse p= 0.011
OS, 5 years Worse p= 0.011
NOTE. † refers to total number of intratumoral CCL1+ cells/mm2
The χ2 test was used for categorical variables. Rs, Spearman rank-correlation.
Boldfacing indicates significant p-values.
A small number of patients did not have complete data.
Table 3.1 – Correlation between total number of intratumoral CCL1+ cells and clinicopathologic
features in invasive ovarian cancer
3.2.2 CCL1 significantly more expressed in cancer tissues
Furthermore, we noted that CCL1-expressing cell distribution was positively skewed
not only in terms of total number but also in terms of compartiments. CCL1-
expressing cells were frequently present peritumorally, in lymphoid-enriched areas
but not detectable in adjacent stromal compartments – Figure 3.5, p. 31. In all
cases expressing cells were immune cells of lymphoid and myeloid lineages.
Moreover, CCL1 was also expressed intratumorally by tumor cells distributed
among the tumor core and present in almost all cases (found in 84% of the tumors)
– Figure 3.5, p. 31. For all further calculations, positive cell total numbers were
determined in representative positive areas of the sections. Expressions by tumor cell
themselves was commonly observed and comparable in intensity with the immune
cell labeling. Thus, we added them from recognition when the computer-aided
determination was run.
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CCL1+ ≤ 150† CCL1+ > 150†
Variable No. % No. % Significance
Total No. of patients 100 49 103 51
Age, years p= 0.424
≤ 60 53 26 52 26
> 60 43 21 55 27
Histological subtype p= 0.988
Serous 75 37 83 41 Rs= 0.001
Mucinous 1 1 1 1
Endometroid 6 3 10 5
Adenocarcinoma (NOS) 7 3 3 2
Undifferentiated 2 1 5 2
Unknown 5 2 5 2
Grade p= 0.265
I 4 2 2 1 Rs= 0.080
II 34 17 33 17
III & IV 56 28 68 33
Unknown 3 1 3 1
Optimal surgical debulking p= 0.372
Radical operation 26 13 23 11 Rs= 0.063
Remaining tumor ≤ 2 cm 32 16 33 16
Remaining tumor > 2 cm 18 9 24 12
Sample laparotomy 0 0 2 1
Unknown 20 10 25 12
OS, 15 years Worse p= 0.001
OS, 5 years Worse p= 0.001
NOTE. † refers to total number of peritumoral CCL1+ cells/mm2
The χ2 test was used for categorical variables. Rs, Spearman rank-correlation.
Boldfacing indicates significant p-values.
A small number of patients did not have complete data.
Table 3.2 – Correlation between total number of peritumoral CCL1+ cells and clinicopathologic
features in invasive ovarian cancer
3.2.3 Association of CCL1 expression with clinicopathologic
parameters
Correlations between total numbers of intra- and peritumoral CCL1-expressing
cells and clinicopathologic parameters are presented in Table 3.1 and 3.2, pp. 33,
34, respectively. The total number of intratumoral CCL1-expressing cells was not
significantly correlated with the patient’s age, histological subtype, grade of the tu-
mor and surgical debulking – Table 3.1, p. 33. Furthermore, we didn’t observe any
significant correlation between total number of peritumoral CCL1-expressing cells
and the patient’s age, histological subtype, grade of the tumor and surgical debulk-
ing – Table 3.2, p. 34. Thus, CCL1 expression seems to occur independently from
these commonly used clinical markers.
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Figure 3.8 – Representative examples of CCL1, CCL22, CCL27, and FoxP3 immuno-staining
in breast cancer. (a) Whole breast cancer tissue section with CCL1-expressing cells. (b) Whole
breast cancer tissue section with CCL22-expressing cells. (c) Whole breast cancer tissue section
with CCL27-expressing cells. (d) Whole breast cancer tissue section with FoxP3-expressing cells.
(a-b-c-d) magnification × 200.
3.3 Expression of chemokines in breast cancer
3.3.1 CCL1, CCL22 and CCL27 all expressed in breast cancer
As can be seen in representative photomicrographs, breast cancer tumor sections
expressed CCL1, CCL22 and CCL27 – Figure 3.8, p. 35. Assessment of all tissue
microarray sections showed a high degree of variability in chemokine-expressing
cell total numbers. This was particularly true for CCL1 (median, 116 cells/mm2;
range, 0 to 1784) and CCL27 (median, 102 cells/mm2; range, 0 to 1378). In both
cases expression in normal breast tissue was significantly lower than in tumor tissue
(p= 0.031 and p= 0.002 for CCL1 and CCL27, respectively) – Figure 3.9, p. 36.
In contrast, although there was a degree of variability in CCL22-expressing cell
total numbers in tumors (median, 29 cells/mm2; range, 0 to 189), fewer expressing
cells were observed than for CCL1 and CCL27. Moreover, the total number of
cells expressing CCL22 in tumor tissue was not significantly different from normal
breast tissue (p= 0.359) – Figure 3.9, p. 36.
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Figure 3.9 – Total number of CCL1-, CCL22-, CCL27-, and FoxP3-expressing cells in normal
breast tissue compared to breast tumor tissue. Median and IQR of all chemokines and FoxP3 cell
numbers. Mann-Whitney U test. *P< 0.05; **P< 0.005; ***P< 0.001.
3.3.2 CCL1 and CCL27 significantly more expressed in cancer
tissues
Furthermore, we noted that CCL1-, CCL22- and CCL27-expressing cell distri-
butions were positively skewed not only in terms of total number but also in terms
of compartiments. CCL1- and CCL27-expressing cells were frequently present in
lymphoid-enriched areas and not detectable in adjacent stromal compartments –
Figure 3.8, p. 35. On the contrary, CCL22-expressing cells were more equally dis-
tributed in the tumor and likely to be detected in adjacent stromal compartments
– Figure 3.9, p. 36. For all further calculations, positive cell total numbers were
determined in representative positive areas of the sections. In all cases expressing
cells were immune cells of lymphoid and myeloid lineages. Expressions by tumor
cell themselves was only anecdotally observed and not comparable in intensity with
the immune cell labeling. Thus, we excluded them from recognition when the
computer-aided determination was run.
3.3.3 FoxP3+ cells significantly more infiltrated in cancer tissues
To further characterize possible associations between Treg infiltration and the ex-
pression of our candidate chemokines, we labeled FoxP3 on the same tissue mi-
croarray sections – Figure 3.8, p. 35. Like for the chemokine, the total number
of infiltrating Treg presented a high degree of variability (median, 131 cells/mm2;
range, 0 to 1624). Compared with normal breast tissue infiltration, Treg infiltra-
tion in tumor tissue was significantly higher (p< 0.001) – Figure 3.8, p. 35. Treg
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CCL1+ ≤ 100† CCL1+ > 100†
Variable No. % No. % Significance
Total No. of patients 87 45 106 55
Age, years p= 0.209
≤ 50 26 13 42 22
> 50 61 32 64 33
Nodal status p= 0.085
Negative 18 10 11 6
Positive 63 36 85 48
Tumor size, cm p> 0.999
≤ 2 17 9 21 11
> 2 69 37 82 43
Grade p= 0.094
II 41 21 36 19
III 45 24 68 36
ER-α status p< 0.001
Negative 30 16 64 34
Positive 55 30 38 20
PgR-α status p= 0.795
Negative 50 27 63 33
Positive 35 19 39 21
Her2 status p= 0.088
Negative 62 33 64 34
Positive 22 11 41 22
OS, 15 years Worse p= 0.033
OS, 5 years Worse p= 0.031
NOTE. † refers to total number of CCL1+ cells/mm2
Abbreviations: ER-α, estrogen receptor-alpha; PgR-α, progesterone receptor-alpha;
Her2, human epidermal growth factor receptor 2.
The χ2 test was used for categorical variables. Boldfacing indicates significant p-values.
A small number of patients did not have complete data.
Table 3.3 – Correlation between total number of CCL1+ cells and clinicopathologic features in
invasive breast cancer
were commonly localized in the vicinity of tumor cells, but were likely to locally
accumulate in lymphoid-enriched areas.
3.3.4 Association of CCL1, CCL22 and CCL27 expressions with
clinicopathologic parameters
Correlations between total numbers of CCL1-, CCL22- and CCL27-expressing
cells and clinicopathologic parameters are presented in Table 3.3, 3.4, and 3.5, pp.
37, 38, 39, respectively. The total number of CCL1-expressing cells was not signifi-
cantly correlated with the nodal status, Her2 status and tumor grade. Furthermore,
total number of CCL1-expressing cells strongly correlated with ER-α status (p<
0.001), showing a clear inversion of the ratio ER-α+/ER-α- between the groups –
Table 3.3, p. 37. The total number of CCL27-expressing cells only weakly corre-
lated with the tumor grade – Table 3.5, p. 39. In contrast, no correlation was found
with the total number of CCL22-expressing cells – Table 3.4, p. 38.
Interestingly, there was a significant relationship between the Treg infiltration
in tumors and chemokine-expressing cell total numbers – Table 3.6, p. 40. In
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CCL22+ ≤ 25† CCL22+ > 25†
Variable No. % No. % Significance
Total No. of patients 74 39 116 61
Age, years p= 0.949
≤ 50 25 13 41 22
> 50 49 26 75 39
Nodal status p= 0.312
Negative 14 8 14 8
Positive 55 32 91 52
Tumor size, cm p= 0.548
≤ 2 13 7 25 13
> 2 61 33 87 47
Grade p= 0.811
II 28 15 46 25
III 46 25 67 35
ER-α status p= 0.932
Negative 36 20 58 31
Positive 36 20 54 29
PgR-α status p= 0.256
Negative 48 26 64 35
Positive 24 13 48 26
Her2 status p= 0.320
Negative 51 27 72 39
Positive 21 11 43 23
OS, 15 years Same p= 0.460
OS, 5 years Same p= 0.570
NOTE. † refers to total number of CCL22+ cells/mm2
Abbreviations: ER-α, estrogen receptor-alpha; PgR-α, progesterone receptor-alpha;
Her2, human epidermal growth factor receptor 2.
The χ2 test was used for categorical variables. Boldfacing indicates significant p-values.
A small number of patients did not have complete data.
Table 3.4 – Correlation between total number of CCL1+ cells and clinicopathologic features in
invasive breast cancer
Pearson’s product-moment correlations, we found significant associations between
CCL1- and CCL27-expressing cell total numbers and total number of infiltrat-
ing Treg (p< 0.001, both), but not between CCL22-expressing cell total number
and total number of infiltrating Treg (p= 0.748). The association with CCL1- and
CCL27-expressing cell total numbers was further significant in a multivariate linear
model (p< 0.001 and p= 0.023, for CCL1 and CCL27, respectively) – Table 3.6, p.
40, as plotted in 3d – Figure 3.10, p. 40.
Both CCL1 and CCL27 could therefore actively recruit Treg into the tumors
and our results strongly suggest that we might gain considering them together in-
stead of separately.
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CCL27+ ≤ 80† CCL27+ > 80†
Variable No. % No. % Significance
Total No. of patients 83 43 109 57
Age, years p> 0.999
≤ 50 29 15 39 20
> 50 54 28 70 37
Nodal status p= 0.177
Negative 16 9 12 7
Positive 61 35 87 49
Tumor size, cm p= 0.963
≤ 2 17 9 21 11
> 2 64 34 86 46
Grade p= 0.074
II 39 21 36 19
III 43 23 71 37
ER-α status p= 0.318
Negative 38 20 57 31
Positive 44 24 47 25
PgR-α status p= 0.690
Negative 48 26 65 35
Positive 34 18 39 21
Her2 status p= 0.153
Negative 58 31 67 35
Positive 22 12 42 22
OS, 15 years Trend p= 0.150
OS, 5 years Worse p= 0.031
NOTE. † refers to total number of CCL27+ cells/mm2
Abbreviations: ER-α, estrogen receptor-alpha; PgR-α, progesterone receptor-alpha;
Her2, human epidermal growth factor receptor 2.
The χ2 test was used for categorical variables. Boldfacing indicates significant p-values.
A small number of patients did not have complete data.
Table 3.5 – Correlation between total number of CCL1+ cells and clinicopathologic features in
invasive breast cancer
3.4 Chemokines correlate with worse overall survival
3.4.1 CCL1 expression predict poor patient outcome in ovarian
cancer
The median follow-up period was 32 months (range, 1 to 233), during which 145
patients died from ovarian cancer. Patient groups were defined in respect to the total
number of chemokine-expressing cells (i.e., higher or lower than respective medi-
ans). Patients with high intra- or peritumoral CCL1-expressing cell total numbers
presented strongly reduced median survivals (53 months versus 29 and 60 months
versus 30, for intra- and peritumoral, respectively) – Figure 3.11 and 3.12, pp. 41,
41. Moreover, the OS difference was significant over a long period of time. Survival
of patients with high intratumoral CCL1-expressing cell total number was worse
after 5 years as well as after 15 years follow-up (p= 0.011 both, for survival after 5
and 15 years, respectively) – Table 3.1, p. 33. This was also the case for patients
with high total number of peritumoral CCL1-expressing cell (p= 0.001 both, for
survival after 5 and 15 years, respectively) – Table 3.2, p. 34.
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Linear regression (Pearson)
FoxP3 Number of pairs ρ p-value
CCL1 189 0.4981 2.28 10-13 ***
CCL22 184 0.0237 0.748
CCL27 186 0.3580 4.57 10-07 ***
Multiple linear regression
FoxP3 Estimate Std. error p-value
Intercept 91.518 24.544 2.56 10-4 ***
CCL1 0.2949 0.0505 2.29 10-8 ***
CCL27 0.2942 0.1286 0.023 *
ρ, Pearson’s correlation coefficient.
Table 3.6 – Pearson’s product-moment correlation and multiple linear regression fit to total number
of FoxP3-expressing cells using total number of CCL1-, CCL22- and CCL27-expressing cells as
predictors. *P< 0.05; ***P< 0.001.
Figure 3.10 – Multiple linear regression fit to total number of FoxP3-expressing cells using total
number of CCL1- and CCL27-expressing cells as predictors. The third axis represents the total
number of CCL27-expressing cells; red spots, low CCL27-expression, black spots, high CCL27-
expression.
Consistent with the correlation between intra- and peritumoral expressions, the
analysis for patient groups based on both intra- and peritumorally expressing cell
total numbers showed no difference in the results. Patients with high intra- and
peritumoral expression of CCL1 were regrouped and compared with the others (i.e.,
patients with high expression in none or only one of the two areas).
Median survival of these high-risk patients was comparatively reduced (26 months
versus 53) – Figure 3.13, p. 42. The OS difference was highly significant over the
15 years follow-up (p< 0.001 both, for survival after 5 and 15 years, respectively).
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Figure 3.11 – KM plots of ovarian cancer OS, stratified by a cutoff at the median values for
CCL1 expressed intratumorally.
Figure 3.12 – KM plots of ovarian cancer OS, stratified by a cutoff at the median values for
CCL1 expressed intratumorally.
3.4.2 Prognostic significance of CCL1-expression in ovarian
cancer
Based on these results, we investigated the prognostic significance of high CCL1-
expression in ovarian cancer. Multivariate Cox proportional hazards model showed
that high intratumoral expression of CCL1 was independently associated with worse
41
3. Results
Figure 3.13 – KM plots of ovarian cancer OS, stratified by a global cutoff for CCL1-expressing
cells ( i.e., patients highly expressing CCL1 both intra- and peritumorally against the others).
prognosis (hazard ratio, 1.60; 95% confidence	interval (Conf. Int.), 1.13 to 2.62; p=
0.008) – Table 3.7, p. 42. Peritumoral expression of CCL1 was also independently
associated with worse prognosis (hazard ratio, 1.59; 95% Conf. Int., 1.13 to 2.25;
p= 0.008) – Table 3.8, p. 43. Interestingly, with exception of the adjuvant ther-
apy (hazard ratio, 0.68; 95% Conf. Int., 0.42 to 1.10; p= 0.113), all other common
markers included were independently associated with worse prognosis, according
to the current knowledge. Similar results were obtained when considering only the
first 5 years after surgery.
Conf. Int. hazard ratio†
Variable Hazard ratio† Lower .95 Upper .95 p-value
Tumor grade 1.62 1.13 2.33 0.009 **
Patients’ age 1.74 1.21 2.50 0.003 **
Tumor rest ≤ 2 cm 1.98 1.25 3.12 0.003 **
Tumor rest > 2 cm 2.62 1.54 4.46 < 0.001 ***
Adjuvant therapy 0.68 0.42 1.10 0.113
CCL1 intratumoral 1.60 1.13 2.62 0.008 **
† Obtained using the Cox proportional hazards model.
Table 3.7 – Multivariate Cox proportional hazards model showing hazard ratios for patient con-
ferred by grade, patients’ age, tumor rest size, adjuvant therapies and higher total numbers of
intratumoral CCL1-expressing cells. **P< 0.005; ***P< 0.001.
Thus our results show that high total numbers of CCL1-expressing cells in ovar-
ian cancer correlated with a significantly worse survival over 15 years follow-up and
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Conf. Int. hazard ratio†
Variable Hazard ratio† Lower .95 Upper .95 p-value
Tumor grade 1.54 1.07 2.21 0.020 *
Patients’ age 1.69 1.18 2.42 0.004 **
Tumor rest ≤ 2 cm 1.69 1.07 2.66 0.023 *
Tumor rest > 2 cm 2.25 1.34 3.80 0.002 **
Adjuvant therapy 0.61 0.38 .99 0.046 *
CCL1 peritumoral 1.59 1.13 2.25 0.008 **
† Obtained using the Cox proportional hazards model.
Table 3.8 – Multivariate Cox proportional hazards model showing hazard ratios for patient con-
ferred by grade, patients’ age, tumor rest size, adjuvant therapies and higher total numbers of
peritumoral CCL1-expressing cells. *P< 0.05; **P< 0.005.
was independently associated with worse prognosis.
3.4.3 CCL1 and CCL27 expression predict poor patient outcome
in breast cancer
Figure 3.14 – KM plots of breast cancer OS, stratified by a cut-off at the median values for CCL1.
The median follow-up period was 41 months (range, 1 to 201), during which
185 patients died from invasive breast cancer. Patient groups were defined in respect
to the total number of chemokine-expressing cells (i.e., higher or lower than respec-
tive medians). Patients with high CCL1- or CCL27-expression cell total numbers
in their tumor presented strongly reduced median survivals (53 months versus 35
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and 36, for high CCL1- and CCL27-expression, respectively) – Figure 3.14 and
3.16, pp. 43, 45. However, high total number of CCL22-expressing cells did not
significantly predict a worse outcome (40 months versus 48) – Figure 3.15, p. 44.
Moreover, in the case of CCL1 and CCL27 expression, the OS difference was sig-
nificant over a long period of time. Survival of patients with high CCL1-expressing
cell total number was worse after 5 years as well as after 15 years follow-up (p= 0.031
and p= 0.033, for survival after 5 and 15 years, respectively) – Table 3.3, p. 37. This
was, however, not the case for patients with high total number of CCL27-expressing
cell. Survival difference was similarly signifiant after 5 years, but not any more after
15 years, (p= 0.031 and p= 0.150, for survival after 5 and 15 years, respectively) –
Table 3.5, p. 39.
Applying the same analysis to patient groups based on both CCL1- and CCL27-
expressing cell total numbers showed the most significant result. Patients with high
expression of both CCL1 and CCL27 were regrouped and compared with the oth-
ers (i.e., patients with high expression of none or only one of the two chemokines).
Median survival of these high-risk patients was dramatically reduced (33 months
versus 55) – Figure 3.17, p. 45. Furthermore, the OS difference was highly signifi-
cant over the 15 years follow-up (p< 0.001 and p= 0.002, for survival after 5 and 15
years, respectively).
Figure 3.15 – KM plots of breast cancer OS, stratified by a cut-off at the median values for
CCL22.
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Figure 3.16 – KM plots of breast cancer OS, stratified by a cut-off at the median values for
CCL27.
Figure 3.17 – KM plots of breast cancer OS, stratified by addition of both CCL1- and CCL27-
risk factors ( i.e., patients highly expressing both CCL1 and CCL27 against the others).
3.4.4 Prognostic significance of CCL1- and CCL27-expression in
breast cancer
Based on these results, we investigated the prognostic significance of both high
CCL1- and CCL27-expression in breast cancer. Multivariate Cox proportional
hazards model showed that high expression of both CCL1 and CCL27 was in-
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dependently associated with worse prognosis (hazard ratio, 1.53; 95% Conf. Int.,
1.02 to 2.03; p= 0.016) – Table 3.9, p. 46. Interestingly, with exception of the tu-
mor grade (hazard ratio, 1.44; 95% Conf. Int., 1.02 to 2.03; p= 0.037), no other
common markers included were independently associated with worse prognosis (p=
0.415, p= 0.669, p= 0.787, p= 0.999, and p= 0.240, for tumor size and ER-α, PgR-
α, and Her2 status, respectively). Similar results were obtained when considering
only the first 5 years after surgery.
Conf. Int. hazard ratio†
Variable Hazard ratio† Lower .95 Upper .95 p-value
Tumor grade > 1 1.44 1.02 2.03 0.037 *
Patients’ age > 50 1.15 1.83 1.59 0.415
Tumor size > 2 cm 0.91 0.61 1.37 0.669
ER-α status 1.06 0.69 1.64 0.787
PgR-α status 0.99 0.65 1.53 0.999
Her2 status 1.23 0.87 1.73 0.240
CCL1 & CCL27 1.53 1.02 2.03 0.016 *
† Obtained using the Cox proportional hazards model.
Table 3.9 – Multivariate Cox proportional hazards model showing hazard ratios for patient con-
ferred by grade, patients’ age, tumor size, ER-α status, PgR-α status, Her2 status and higher
total numbers of CCL1- and CCL27-expressing cells. The parameter nodal status is not included
in multivariate analysis because tumors capacity to form metastases is not an independent clinical
parameter in our cohort. *P< 0.05.
Thus our results show that high total numbers of both CCL1- and CCL27-
expressing cells in invasive breast cancer correlated with a significantly worse survival
over 15 years follow-up and were independently associated with worse prognosis.
*
* *
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Discussion 4
— There	cannot	however	be	the	least	doubt, that	the	higher	organ-
isms, as	they	are	now	constructed, contain	within	themselves	the	germs
of	death.
August	Weissmann, philosopher	of	biology, 1889
4.1 Chemokines specifically attracting regulatory T
cells
4.1.1 A brief history of chemokines in cancer
The effect of chemokines on Treg recruitment and tumor escape for patientswith breast cancer is poorly described. Although previous studies associated
increased intratumoral number of CD4+ CD25+ Treg with CCL22 and CCL28 and
reported adversely affected prognosis in ovarian cancer, before our current work the
clinical importance of other chemokines was unknown [15, 16].
Pioneer work was done fifteen years ago and documents the migration of Treg
in response to several CC- and CXC-chemokines [67]. Iellem et. al. described
the strong and preferential migration of Treg in response to CCL1, CCL17 and
CCL22 binding CCR8 and CCR4 (both CCL17 and CCL22), respectively. Si-
multaneously, CCL22 was shown to be expressed by tumor cells and macrophages
and associated with specific recruitment of Treg in ovarian cancer [15].
Here, our results demonstrated that two other chemokines, CCL1 and CCL27
could potentially also attract Treg into tumors. To the best of our knowledge, we
are the first investigating the prognostic significance of CCL1 and CCL27 in hu-
man ovarian and breast cancer. Our results strongly suggest that the total number
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of CCL1- and CCL27-expressing cells has an important role in Treg recruitment
in ovarian and breast cancer, as described for CCL22 and CCL28 in ovarian can-
cer [15, 16].
4.1.2 Our candidates: CCL1, CCL22 and CCL27
Soon after CCL22 became the first candidate by which tumors may foster immune
privilege, CCR10 was added to the list of receptors allowing Treg to migrate in
response to chemokine [69]. It was then rapidly confirmed that CCL28 acts under
tumor hypoxia conditions to recruit Treg in ovarian cancer [16].
Our investigations focused on a broader spectrum of Treg responsiveness to che-
mokines that could potentially allow them to access tumor tissues. This approach
allows, besides comparison of determined CI and EF between chemokines, the val-
idation of CCL1 in a Treg specific recruitment role [67].
Moreover, we provide evidence that CCL27 should be as well considered as
good candidate. CCL27 should therefore be added to the list of chemokine possibly
secreted in tumor to recruit Treg. CCL27 description fits yet well with the current
knowledge as it binds CCR10 known to be preferentially expressed on Treg, in
a same way as CCL28 [69, 70]. Furthermore, CCL27 mediates, via binding to
CCR10, chemotactic responses of skin-associated lymphocytes and is induced by
TNF-α and IL-1β [71].
4.1.3 About the selectivity of our screening
Although particularly striking at first, the determination of only three chemokines
(i.e., CCL1, CCL22 and CCL27) specifically attracting Treg should be considered
in the context of our analysis. We intended to select the most relevant chemokines
under discriminant migration conditions.
The recruitment of Treg by several other chemokines into tumors or inflam-
matory sites has been suggested, like for CCL17 and CCL18 [72, 73]. However,
we used whole PBMC in our migration assays and occasionally observed a slightly
negative T cell migration. This points out that our conditions were particularly dis-
criminant and other cell populations could have slowed T cells in their migration.
Unexpectedly, we observed no migration for CCL28, which is, however, besides
CCR10, also binding to CCR3 [74]. Consistant with this, cells recruited through
binding to CCR3 could have handicapped T cell migrations. Moreover, it seems
to have been the case for most of the chemokines not inducing migration in our
conditions (i.e., CCL4, 11, 13, 14, 15, 16, 24, 26, and CCL28). All of them bind to
the very redundant chemokine receptors CCR1, 2, 3, or CCR5. Other receptors for
CCL17 and CCL18 are not known, but our results suggest it as a possibility. Indeed,
in human, CCL17 and other chemokines (i.e., CCL22 and CX3CL1) belongs to
a cluster on chromosome 16 [75]. CCL18 belongs to the big MIP-cluster, like
CCL4, CCL13, CCL14, CCL15, CCL16, and consists of a fusion of two CCL3-
like genes [76, 77]. Thus, they both could potentially bing to more than one receptor
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– not like our three candidates – and this may explain our results, even if they are
likely to attract Treg otherwise.
4.2 The case of ovarian cancer
4.2.1 CCL1 produced by tumor and immune cells
Based on work done previously, we decided to explore the chemokine expressions
of our candidates in ovarian cancer [15, 16]. Unfortunately, due to the few samples
available, we were only able to realize one labeling for this cohort. Labelings for
FoxP3 and CD8 have been previously published [68].
In the same manner as for the already documented expressions of CCL22 and
CCL28, we found an expression of CCL1 in tumor tissue [15, 16]. Moreover,
this chemokine is expressed by tumor cells as well as by infiltrating immune cells.
Production of CCL22 by tumor cells following detection by immune cells was de-
scribed in vitro, and associated with the recruitment of Treg [78]. Importantly, we
also observed and quantified CCL1 expression by infiltrated immune cells. Both ex-
pressions were significantly higher in tumor tissue compared to the basal expression
in normal ovarian tissue.
4.2.2 Both expressions correlated with reduced overall survival
High total number of CCL1-expressing cells correlated with reduced OS. The na-
ture of the producing cells, as well as their localizations - intra- or peritumoral -
does not seem to influence the results of the KM analysis. Moreover, both cor-
related with the Treg infiltration previously described (Pearson’s product-moment
correlation; p= 0.050 and p= 0.013, intra- and peritumoral expression, respectively),
consistent with a possible recruitment into the tumor of Treg by CCL1 [68].
Recently, higher plasma CCL22 levels of women at stage IV FIGO, associated
with higher peritoneal fluid Treg percentage was also described [79]. We, however,
observed no correlation between total number of CCL1-expressing cells and com-
monly used clinical markers. This could be due to the fact, that we only included
women classified at stage FIGO III and should be explored in the future, since the
CCL1-production kinetic by tumor cells or immune cells could plays a role in the
disease.
4.2.3 CCL1 could serve as a new biomarker in ovarian cancer
Here we provide the first demonstration that CCL1-expression recruits CD4+ CD25+
FoxP3+ Treg cells, which can dampen effector T cell function and promote tumour
progression. This finding reinforces the link between chemokines, Treg and periph-
eral tolerance.
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This clearly appears in our Cox proportional hazards model analysis, which
showed that a higher total number of both CCL1-expressing cells was indepen-
dently associated with a higher risk of death (hazard ratio, 1.60; 95% Conf. Int.,
1.13 to 2.62; p= 0.008) in a model that included the usual parameters evaluated in
clinical studies. All other common parameters (i.e., tumor grade, patient age, tumor
rest) were significantly associated with patient worse outcome. Adjuvant therapy to
the surgery presented a reduced hazard ratio (0.68; 95% Conf. Int., 0.42 to 1.10; p=
0.113), although not significant. Thus leading us to conclude, that these patients
might had benefit from an associated immunotherapy targeting CCL1.
This hypothesis is strongly supported by the observation of Treg migration in
response to CCL1 in the past, and the association of Treg infiltration and reduce OS
by other groups [15, 16, 67]. It was suggested, that anti-CCR4 treatment augments
anti-tumor immunity in cancer patients by selectively depleting Treg cells [80, 81].
Our data suggest, that the same effect could possibly be reached with an anti-CCR8
treatment. Moreover, CCR8 was implicated in donor Treg survival and is critical for
the prevention of murine graft-versus-host disease [82]. This implies, that blockade
of CCR8, the receptor for CCL1, could represent a two edged sword therapeutic
option, affecting Treg migration as well as their survival.
4.3 The case of breast cancer
4.3.1 CCL22 similarly produced in tumor tissue
Surprisingly, the total number of CCL22-expressing cells in tumors was not sig-
nificantly higher than in normal breast tissue. However, our computer-aided cell
recognition focuses on activated T cells, DC, monocytes, or macrophages [67, 83].
Although CCL22 production by tumor cells was documented, we excluded
them from recognition. They represented in breast cancer a minor light expressing
tumor cell population and we decided to focus on expressing immune cell popula-
tions in our study [78, 84]. Thus, since our methods differ, it may not be surprising
that a high total number of CCL22-expressing cells did not correlate with total
number of infiltrating Treg in tumors and reduced OS.
4.3.2 CCL1 and CL27 produced in tumor tissue
On the contrary, CCL1 and CCL27 both correlate with total number of infiltrating
Treg in tumor and reduced OS. In a recent study, Hoelzinger et. al. described
that the blockade of CCL1 inhibits Treg suppressive function without affecting T
effector responses in a murine model [85]. More recently, Das et. al. suggested
that tumor cell entry into the lymph node is controlled by CCL1 [86]. Without
presuming a role in T cell migration, these data support at least the specificity of
the CCL1 action on Treg among immune cells and suggest possible other roles for
this chemokine on tumor cells.
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High total number of CCL1-expressing cells also strongly correlate with ER-
α in a same way as described for Treg, which supports our hypothesis, that it
could attract these cells [53]. During the last ten years, CCL27 was implicated
several times in tumor progression and immune escape in cutaneous malignant
melanoma [87, 88, 89, 90].
4.3.3 CCL1 and CCL27 could be targeted in immunotherapy
Furthermore, CCL1 and CCL27 fit the total number of infiltrating Treg as predic-
tors in a multivariable analysis. These investigations have led us to the hypothesis
that the high expression of two chemokines, instead of only one, may enhance the
recruitment of Treg and facilitates the creation of an immunosuppressive milieu.
This hypothesis is strongly supported by the observation of a synergistic rather
than an additive effect in response to a combination of suboptimal doses of CCL1
and CCL22 [67]. Prerequisite was the high total number of CCL1- and CCL27-
expressing cells found in breast cancers, which could act synergistically to recruit
Treg, binding to both CCR8 and CCR10. This idea was supported by the reduced
OS observed for patients with high total numbers of both CCL1- and CCL27-
expressing cells. Both chemokines seem to be required because recruitment could
not occur via a distinct chemokine axis, as very recently suggested in a murine
model [91].
This was confirmed in our Cox proportional hazards model analysis, which
showed that a higher total number of both CCL1- and CCL27-expressing cells
was independently associated with a higher risk of death (hazard ratio, 1.50; 95%
Conf. Int., 1.07 to 2.10; p= 0.019) in a model that included the usual parameters
evaluated in clinical studies. Neither tumor size nor receptor status were signifi-
cantly associated with patient outcome. The patients in our cohort had all docu-
mented metastases during the course of their disease. It may be worth to mention,
since at least CCL1 was implicated in tumor cell entry into the lymph node [86]. A
possible explanation for the worse prognosis may be due, in part, to this association
with the metastatic process.
4.4 Conclusion
4.4.1 Comparison between ovarian and breast cancer chemokine
expressions
Our work presents advantages compared to former studies. We realize a large che-
mokine screening among the CC-chemokine family. This allows us, besides a bet-
ter comparison among these chemokines and their effect on Treg, to exclude the
possibility for all others to recruit Treg specifically. Fact being corroborated by pre-
vious studies, which described only CCR4, CCR8 and CCR10 (receptors for our
three candidates, CCL22, CCL1, and CCL27, respectively) specifically expressed
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on Treg [15, 16, 67]. In fact, our own work on chemokine receptors fails to find
other receptors overexpressed on Treg, thus leading us to conclude to the probable
absence of other candidate.
Additionally, we provided here the possibility to compare the effect of chemo-
kines on Treg recruitment in two cancer types. In both cases, we found a comparable
effect of CCL1 on the patients’ OS, as well as almost identical cell distributions per
mm2 (150 versus 116 cells/mm2, in ovarian and breast cancer, respectively). More-
over, our Cox proportional hazards model analysis revealed a similar effect of chemo-
kine productions in the two cancer types (hazard ratio, 1.60 versus 1.50, in ovarian
and breast cancer, respectively). Importantly, the hazard ratio was comparable to
the other common clinical parameters in the case of ovarian cancer, thus leading us
to conclude that CCL1 might be a good candidate for adjuvant immunotherapy.
Finally, the case of breast cancer enabled us to compare the effect of more than
one chemokine and led us to propose, that they might act together to recruit Treg.
Patients with a high expression of both CCL1 and CCL27 presenting a significantly
higher risk of death (hazard ratio of 1.50). In this cohort, all patients had an history
of metastasis and commonly used clinical markers were incapable of risk predictions.
Thus, it might be worse to block more than one chemokine receptor. It was also the
opportunity to explore the CCL22 production of the immune cell alone, since we
observed almost no expression by the tumor cells. This was the most striking differ-
ence compared to ovarian cancer, where tumor cells were independently massively
producing chemokine (i.e., CCL1 in our work, or CCL22 and CCL28, described
by others) leading to worse survival of patients [15, 16].
4.4.2 Limitation of our investigations
There are limitations of our investigation. It is a retrospective evaluation; however,
we investigated a prespecified hypothesis largely documented in prospective murine
studies, and we supported our data by complete migration analysis. Since in our
breast cancer cohort all patients had a documented history of metastases, we had
to exclude the nodal status in the multivariate Cox model. Tumors invasion into
lymph node have not been an independent clinical parameter. In our analysis we
presuppose that FoxP3 is a valid Treg marker. There have been, however, publi-
cations questioning this assumption in the past [92, 93]. Some evidence also sug-
gests that FoxP3+ Treg subpopulations may be involved in tumor suppressive func-
tions [94, 95]. For now FoxP3 remains the most established and understood Treg
cell marker we know [35, 96, 97, 98].
4.4.3 Concluding remark
Validation of our findings in additional investigations might open the way for new
therapeutic approaches of the combination of conventional chemotherapy with im-
munotherapy. Blockade of only one chemokine or chemokine receptor may not be
sufficient to overcome a Treg associated immunosuppressive milieu. Our results in-
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dicate that depleting both CCL1 and CCL27 or blocking both CCR8 and CCR10
might improve the efficacy of adoptive T cell transfer. This study strongly supports
further investigation of this line of potential therapeutic intervention.
*
* *
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Appendix 5
— Nous	trouvons	de	tout	dans	notre	mémoire. Elle	est	une	espèce	de
pharmacie, de	laboratoire	de	chimie, où	on	met	au	hasard	la	main	tantôt
sur	une	drogue	calmante, tantôt	sur	un	poison	dangereux.
Marcel	Proust, novelist, 1923
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5.2 Eidesstattliche Versicherung
Ich erkläre hiermit an Eides statt,
dass ich die vorliegende Dissertation mit dem Thema
Role of regulatory T cells and associated chemokines in human gynecological tumors
selbständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedi-
ent und alle Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernom-
men sind, als solche kenntlich gemacht und nach ihrer Herkunft unter Bezeichnung
der Fundstelle einzeln nachgewiesen habe.
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher
oder in ähnlicher Form bei einer anderen Stelle zur Erlangung eines akademischen
Grades eingereicht wurde.
München, den 28 September 2015 Christoph Paul Freier
*
* *
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